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Carcinoid Heart Disease: 
Biochemical and Echocardiographic Assessment 
By Rebecca Dobson 
 
Abstract 
Introduction 
Carcinoid heart disease is a para-neoplastic complication of 
neuroendocrine tumours, occurring in patients with carcinoid syndrome. 
Due perhaps to its rarity, there is conflicting evidence in the literature with 
regard to the optimum method of diagnosis and assessment of the 
condition. The aim of this thesis is to quantify the variation in clinical 
practice with regard to carcinoid heart disease and to identify the optimum 
biochemical and echocardiographic methods for the screening, diagnosis 
and assessment of progression of the condition. 
 
Methods 
Patients were prospectively recruited from specialist neuroendocrine 
clinics in the North of England and underwent evaluation of their 
symptoms, disease burden, biochemical markers, and transthoracic 
echocardiography.  
 
Results 
Wide variation in the screening and clinical management of carcinoid heart 
disease was identified. A total of 239 patients were recruited to the study 
and the prevalence of carcinoid heart disease was 21%. From a panel of 
biomarkers, N-terminal pro brain natriuretic peptide (NTproBNP) and 
plasma 5-hydroxyindoleacetic acid (5HIAA) were the most sensitive and 
specific biomarkers for the presence of carcinoid heart disease. All 
previously described echocardiographic scoring systems discriminated 
highly between those with/without carcinoid heart disease, with no single 
score performing significantly better than another. The complexity of the 
scoring systems varied considerably, with the simplest scoring system 
better suited for screening and the more complex systems most useful for 
pre-surgical assessment. A disease progression rate of 9% was 
demonstrated, with a further 22% of patients dying during the study. 
Plasma 5HIAA was the greatest predictor of disease progression and 
death. 
 
Conclusion 
There is considerable heterogeneity across the UK and Ireland in multiple 
aspects of screening and management of carcinoid heart disease. 
NTproBNP and plasma 5HIAA should be used to screen for the disease 
with transthoracic echocardiography reserved for those with elevated 
biomarkers. A simple echocardiographic scoring system should be used to 
screen for the disease, with the more complex scoring systems reserved 
for those patients with established disease. Biomarkers can also be used 
to predict risk of disease progression and death.  
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1.1 Introduction and Aims 
 
Neuroendocrine tumours (NETs) are rare, slow-growing malignancies that 
are usually located in the gastrointestinal system. They were first 
described by Langhans in 1867 (1), but it wasn’t until 1907 that the term 
carcinoid was used to distinguish these neoplasms from adenocarcinomas 
(2). The tumours secrete substances such as serotonin, which lead to the 
carcinoid syndrome and are also responsible for the significant para-
neoplastic complication of carcinoid heart disease.  
 
The first case of carcinoid heart disease was documented by Biork et al. in 
1952 (3). It is defined as “the presence of characteristic thickening, 
decreased excursion, and/or retraction of valvular leaflets (with associated 
evidence of valvular stenosis or regurgitation) in the absence of other 
causes” (4). Carcinoid heart disease is a relatively rare phenomenon and 
consequently there is a lack of clarity in the literature regarding how best 
to screen for and manage the condition.  
 
The aims of this thesis are to: 
• Explore the variation in screening and clinical management of 
patients with carcinoid heart disease.  
• Determine the most sensitive and specific biochemical markers for 
the diagnosis of carcinoid heart disease.  
• Elucidate the most appropriate echocardiographic scoring system 
for carcinoid heart disease.  
• Examine the factors associated with both the progression of and 
death from carcinoid heart disease. 
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1.2 Neuroendocrine Tumours 
 
Neuroendocrine, or carcinoid tumours are rare, slow-growing tumours, 
which most commonly arise from the enterochromaffin cells in the 
gastrointestinal tract. They can however arise anywhere within the body, 
with the bronchopulmonary system being the second most common site 
(5).  
 
Carcinoid tumours are characterised by their ability to secrete a variety of 
vasoactive substances, including 5-hydroxytryptamine (serotonin), 
tachykinins, histamine and prostaglandins. These substances are in part 
or wholly responsible for both the carcinoid syndrome (facial flushing, 
diarrhoea and bronchospasm) (6) and carcinoid heart disease. Serotonin 
is a neurotransmitter capable of modulating neural activity, but it also plays 
a role in a variety of biological processes including bowel motility, 
cardiovascular function and bladder control (7). With regard to the heart, 
serotonin is involved in several different aspects of cardiac function. It 
plays a role in electrical conduction (complex regulation of the sinus node 
and atrioventricular node) and in heart valve closure (serotonin receptor 
activation on valve leaflets is thought to trigger mitosis, thereby increasing 
valve leaflet area and interfering with valve closure).  
 
The incidence of NETs has significantly increased in recent years, with an 
age-adjusted incidence of 1 per 100,000 in 1973, and 5 per 100,000 in 
2004 (8). This is likely to be due in part, to improvements in the diagnosis 
of the disease.  
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1.21 Medical Management of NETs 
 
Over the past three decades numerous therapeutic advances have been 
made in the treatment of NETs (figure 1.1).  
 
 
 
  
  
 
Figure 1.1 Timeline of NETs 
 
In terms of medical therapy, somatostatin analogues (SSAs) are the 
mainstay of treatment for patients with carcinoid syndrome. Through their 
action on somatostatin receptors, they inhibit the secretion of a variety of 
peptides and amines including serotonin (9). This achieves both 
biochemical and symptomatic improvement in up to 70% of patients (10). 
Furthermore, following the landmark trials PROMID (11) and CLARINET 
(12), SSAs are now known to be beneficial in asymptomatic patients as 
they have an anti-proliferative effect, which can slow or prevent disease 
progression. 
 
SSAs are commercially available as octreotide and lanreotide in both 
immediate release and long acting forms, and are manufactured by the 
pharmaceutical companies, Ipsen and Novartis. Long-acting formulations 
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of SSAs are used most commonly, with the short-acting preparations 
reserved for patients with refractory symptoms, the peri-operative period 
and for the management of carcinoid crisis (13). SSAs are usually well 
tolerated, with generalised abdominal pain the most frequently 
experienced side effect (10). Other adverse effects include injection site 
irritation, nausea, vomiting, and less frequently, hypothyroidism, 
cholecystitis and cholelithiasis. Acute pancreatitis, hepatitis and QT 
interval prolongation have been reported rarely.   
 
Interferon alfa is also used in the treatment of NETs and there is limited 
evidence that it can induce disease stabilisation (14). The drug is used 
either as a sole agent or more commonly, in conjunction with SSAs to treat 
patients with refractory carcinoid syndrome (15). Symptomatic 
improvement with interferon alfa occurs in around 50% of patients, but its 
use is limited by side effects such as malaise, weight loss and fatigue (14). 
 
In recent years the use of the cytotoxic agent everolimus has been 
investigated in patients with advanced NETs (16). The drug was 
associated with a significant biochemical improvement, with marked 
reductions in 5-hydroxyindoleacetic acid (5HIAA) noted when compared to 
placebo. Further research is required to assess symptom control with 
everolimus and it must be used with caution in those with carcinoid heart 
disease due to its propensity to cause oedema.  
 
Peptide receptor radionuclide therapy is an established treatment for 
patients with inoperable or progressive disease and those with symptoms 
refractory to medical therapy (17). The two most commonly used 
radioisotopes are 177Lutetium and 90Ytrium, which are attached to a SSA 
via the chelating agent DOTA. This intervention is associated with tumour 
regression and symptomatic benefit in the vast majority of patients (18) but 
haematological and renal toxicity have been reported. 
 
Pasireotide is a novel SSA, with a high binding affinity for somatostatin 
receptors one, two, three and five compared to octreotide and lanreotide 
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which have a high specificity for somatostatin receptor two only. The drug 
has had mixed results in recent phase II and III clinical trials, although 
patient numbers were small and more data are required before 
conclusions can be drawn (19,20).  
 
Finally, in recent years a serotonin synthesis inhibitor has been developed, 
telotristat epitrate. This has recently completed a phase III clinical trial (yet 
to be published) but in phase II trials, has been associated with both 
significant biochemical and symptomatic improvement in patients with 
carcinoid syndrome not controlled with SSAs (21,22). 
 
1.22 Surgical Management of NETs 
 
Surgical resection of local-regional disease is the only potentially curative 
treatment for patients with midgut NETs (15). Other liver-directed 
therapies to reduce tumour load include chemo-embolisation and radio-
frequency ablation. Trans-catheter embolisation reduces the burden of the 
NET, thereby also reducing hormone levels in patients with hepatic 
metastases (23).   
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1.3 Carcinoid Heart Disease 
 
1.31 Pathophysiology 
 
Carcinoid heart disease, also known as Hedinger Syndrome, was first 
described in 1954 (24). It is defined as “the presence of characteristic 
thickening, decreased excursion, and/or retraction of valvular leaflets (with 
associated evidence of valvular stenosis or regurgitation) in the absence 
of other causes” (4).  
 
The mechanism of valve injury in carcinoid heart disease is not completely 
understood. Patients with carcinoid heart disease have higher circulating 
levels of serotonin compared to those without cardiac involvement, 
implying that serotonin released from the NET contributes to the 
development of the condition (25). The pathophysiology has been further 
inferred from human and animal studies with increased plasma 
concentrations of serotonin strongly implicated in several studies. Firstly, 
the specific serotonin re-uptake inhibitors fenfluramine and 
dexfenfluramine, used as appetite-suppressant drugs, and the ergot 
alkaloids, ergotamine and methysergide, used in the treatment of 
migraine, are known to cause valvular fibrosis (26). Secondly, in an in vivo 
rodent model of carcinoid syndrome in which there were significant 
increases in plasma serotonin, mice exhibited fibrotic cardiac valvular 
disease, which was abrogated by SSAs (27). Furthermore, high dose, long 
term oral administration of serotonin leading to valvular heart disease has 
been described in rabbits (28). Other mechanisms are also thought to 
contribute to the pathophysiology of the disease, with activin A (29) and 
connective tissue growth factor (30,31) both associated with the 
development of carcinoid heart disease.  
 
Microscopically, the cardiac manifestations are characterised by plaques 
of fibrous tissue, which contain myofibroblasts within an extracellular 
matrix that consists mainly of collagen and a myxoid matrix, with an 
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absence of elastic fibres (32,33). Carcinoid plaques can be deposited 
anywhere in the heart, but have a predilection for the right side (85% of 
cases), particularly the tricuspid valve (figure 1.2). The septal and anterior 
tricuspid valve leaflets are most frequently affected, with the posterior 
leaflet often remaining relatively mobile (34). Interestingly, plaques tend to 
occur on the downstream side of valves, i.e. the ventricular aspect of the 
tricuspid valve and the pulmonary arterial aspect of the pulmonary valve 
(35). This plaque formation, and subsequent endocardial thickening 
results in retraction and fixation of the valve leaflets, which causes valvular 
regurgitation and/or stenosis and can ultimately lead to right heart 
dilatation and failure (figure 1.3). 
 
 
Figure 1.2 Carcinoid heart disease. Insert shows pulmonary stenosis. The 
leaflets of the tricuspid valve are thickened. Fibrous plaques are deposited 
on the lining of the right ventricle and pulmonary trunk (36). 
 
Left-sided valve involvement has been reported in up to 15% of cases 
(37,38). Carcinoid heart disease affecting the mitral and aortic valves only, 
which then progressed to right-sided disease has also been described 
(39,40). In the majority of cases, the left heart is relatively protected, as 
the damaging substances secreted by the NET are inactivated by 
pulmonary monoamine oxidase activity (41). However patients with 
bronchial carcinoid, a patent foramen ovale or those with poorly controlled, 
 23 
severe carcinoid syndrome that overwhelms the pulmonary degradative 
capacity may develop left sided lesions (42,43). Distinct from carcinoid 
heart disease, myocardial carcinoid metastases have also been described 
(44,45).  
 
The majority of patients with cardiac involvement have hepatic 
metastases, which allow large quantities of secretory substances to reach 
the heart without inactivation by the liver. However, carcinoid heart 
disease has also been described in patients with ovarian primary tumours 
without hepatic metastases (46). The venous drainage of the ovary 
bypasses the portal circulation and therefore carcinoid heart disease can 
develop in the absence of hepatic involvement.  
 
1.32 Prevalence  
 
The prevalence of carcinoid heart disease varies in the literature (table 
1.1), possibly due to differences in the clinical populations studied and 
advances in the treatment of NETs in recent years. Nevertheless, this 
complication affects a significant proportion of patients with metastatic 
neuroendocrine disease (47). As the management of carcinoid heart 
disease improves, patients are living longer with the condition and 
therefore it may have more of an impact on the patient in terms of both 
quality of life, and overall NET management.  
 
Carcinoid heart disease is most common in patients with NETs of small 
bowel origin (72%) followed by lung, large bowel, pancreas, appendix and 
ovarian origin (48). In approximately one fifth of cases, the primary tumour 
site cannot be determined (42). The mean age at diagnosis of carcinoid 
heart disease is 59 years, and the condition is slightly more prevalent in 
males (60% of cases) (48). 
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Paper Clinical setting 
No of 
patients 
Only patients with 
carcinoid 
syndrome 
included? 
Proportion of 
patients with 
liver metastases 
Proportion of 
patients taking 
SSAs 
Prevalence of 
carcinoid heart 
disease 
Pellikka et al., 1993 (42) Mayo Clinic, USA 125 Yes Uncertain 57% 56% 
Denney et al., 1998 (49) 
Vanderbilt University Medical Center, 
USA 
23 Yes 70% 100% 
35% 
 
Westberg et al., 2001 (50) 
Sahlgrenska University Hospital, 
Sweden 
52 Yes Uncertain Uncertain 77% 
Zuetenhorst et al., 2003 (51) 
Netherlands Cancer Institute, 
Netherlands 
37 No 92% Uncertain 24% 
Zeutenhorst et al., 2004 (52) 
Netherlands Cancer Institute, 
Netherlands 
32 No 91% Uncertain 28% 
Bhattacharyya et al., 2008 (53) Royal Free Hospital, UK 200 Yes 95% 76% 19.5% 
Bhattacharyya et al., 2008 (54) Royal Free Hospital, UK 150 Yes 97% 72% 20% 
Korse et al., 2009 (55) 
Netherlands Cancer Institute, 
Netherlands 
102 No 83% Uncertain 67% 
Mansencal et al., 2010 (56) Hôpital Ambroise Paré, France 80 Yes 100% 80% 33% 
Bergestuen et al., 2010 (29) Oslo University Hospital, Norway 71 No 87% 45% 21% 
SSAs somatostatin analogues 
Table 1.1 Prevalence of carcinoid heart disease 
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1.33 Clinical Presentation  
 
Patients with significant carcinoid heart disease will, on occasion, present 
with symptoms of right heart failure (dyspnoea, fatigue and ankle swelling) 
(57). However, it is important to note that a substantial proportion of 
patients with considerable cardiac involvement will have no cardiovascular 
signs or symptoms (34). In those with clinical signs, a raised jugular 
venous pressure with a prominent ‘V’ wave, ascites or pulsatile 
hepatomegaly may be present (58). The murmur of tricuspid regurgitation 
is pan-systolic and usually appreciated best at the left sternal edge. It 
classically increases in intensity during inspiration. Pulmonary 
regurgitation produces an early diastolic murmur and pulmonary stenosis 
a systolic murmur, heard best in the left second and third intercostal 
spaces. Clinical assessment including New York Heart Association 
(NYHA) classification and physical examination to identify cardiac 
murmurs or peripheral oedema is rarely sufficient, even with disease 
severe enough to warrant valve replacement (54).  
 
Electrocardiographic (ECG) changes are non-specific but may include 
sinus tachycardia, right bundle branch block and P pulmonale in the 
inferior leads (59). A variety of arrhythmias have been associated with 
carcinoid heart disease including paroxysmal atrial tachycardia (59) and 
complete heart block (60). Other clinical presentations including 
constrictive pericarditis (61), restrictive cardiomyopathy (62) and ST 
segment elevation myocardial infarction secondary to coronary spasm (63) 
have all been described.  
 
1.34 Biomarkers  
 
Biochemical markers are useful surrogates for assessing the presence 
and progression of neuroendocrine disease. They have a role in the 
assessment of the response to treatment and may also serve as 
prognostic indicators (64). The measurement of biomarkers is non-
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invasive, risk free and in most cases, relatively cheap when compared with 
imaging investigations.  
 
Historically, well-established NET-specific biomarkers have been used in 
the assessment of carcinoid heart disease. However, in the late nineties 
N-terminal pro-brain natriuretic peptide (NTproBNP) was identified as a 
marker of left ventricular systolic dysfunction (65,66) and its value in the 
diagnosis and assessment of carcinoid heart disease was then recognised 
in 2008 (53).  
  
5-Hydroxyindoleacetic Acid 
As the development and progression of carcinoid heart disease is thought 
to be related to serotonin, it might be expected that plasma serotonin, or 
one of its metabolites, is a useful biochemical correlate of disease 
severity. Urinary levels of 5-Hydroxyindoleacetic acid (5HIAA), the main 
metabolite of serotonin, have been linked with the presence and 
progression of carcinoid heart disease (49,51) but its measurement is not 
without problems. Patients do not like to collect urine for 24 hours, and the 
result is affected by diet (foods containing tryptophans such as sesame 
seeds, milk and oats). More recently, a single measurement of plasma 
5HIAA has been demonstrated to be proportional to urinary 5HIAA and 
has identical clinical correlation with other biomarkers used in the 
diagnosis and monitoring of NETs (67).  
 
Chromogranin A 
Chromogranin A (CgA) is present in the chromograffin granules of 
neuroendocrine cells and is used routinely as a biomarker in patients with 
NETs (68). The concentration of CgA has been associated with the 
prevalence of, and survival from, carcinoid heart disease (55). Korse et al. 
demonstrated a cut off 784 mcg/l with 73% sensitivity and 75% specificity 
for carcinoid heart disease (55). Its use in the monitoring of treatment of 
NETs is recommended in international consensus guidelines (69,70). 
However, CgA is commonly associated with false-positive results due to 
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high concentrations found with proton pump inhibitor therapy and in 
patients with renal impairment (71).  
 
Chromogranin B 
Chromogranin B (CgB), a calcium binding protein, is a regulator of 
cardiomyocyte signalling pathways that mediate hypertrophy and heart 
failure and is thought to be secreted from both the ventricles and the 
adrenal glands (68). It is also present in the secretory granules of 
neuroendocrine cells and therefore is a useful tumour marker in the 
assessment of neuroendocrine disease (72). CgB has the advantage over 
CgA of not being affected by proton pump inhibitor therapy or renal 
impairment (72).  
 
Neurokinin A 
Neurokinin A (NkA), a tachykinin which has effects on gastrointestinal 
motility, flushing and vasodilation is stored and secreted by midgut 
carcinoid tumours. It is used as a prognostic marker as it is a strong and 
independent predictor of premature death in these patients (73).  
 
N-terminal Pro-Brain Natriuretic Peptide 
NTproBNP is the most useful biomarker to date used in the diagnosis and 
assessment of carcinoid heart disease. NTproBNP is a neurohormone 
released mainly from the ventricles, but also from the atria in response to 
an increase in wall stress, as a result of volume and pressure overload 
(74). BNP is synthesised as pro-BNP, released into the circulation and 
cleaved into the physiologically active BNP and the inactive, stable 
degradation product NTproBNP.  
 
NTproBNP has both diagnostic and prognostic significance for cardiac 
involvement (52,55). Bhattacharyya et al. and subsequently Korse et al.  
found similar cut-off levels of 260pg/ml and 280pg/ml for the detection of 
carcinoid heart disease in patients with carcinoid syndrome. 
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Bhattacharyya et al. demonstrated that NTproBNP is a sensitive and 
specific marker for the presence of carcinoid heart disease, and the 
authors advocated its use in the screening of the disease (53). This was 
corroborated in 2009 by Korse et al. who concluded that NTproBNP is 
helpful in the diagnosis of carcinoid heart disease, and also has a role in 
the timing of cardiac valve surgery (55). 
 
Novel and Emerging Biomarkers 
As fibrosis is an important feature of carcinoid heart disease, there has 
been interest in the role of growth factors with fibrogenic properties, such 
as Activin A and transforming growth factor-β. Bergestuen et al. found that 
Activin A was an independent predictor of carcinoid heart disease, and 
had an 87% sensitivity and 57% specificity for cardiac involvement (29). 
 
Connective tissue growth factor is a matricellular protein that is up-
regulated in many fibrotic diseases. Patients with mild or greater degrees 
of tricuspid regurgitation have raised levels of connective tissue growth 
factor and the biomarker is an independent predictor of right ventricular 
(RV) function in patients with NETs (30).  
 
Galectin 3 is a novel marker of myocardial fibrosis, produced by 
macrophages and cardiac fibroblasts (75). It is associated with left 
ventricular remodelling and is a predictor of mortality in patients with 
severe chronic heart failure. Its value in the diagnosis or monitoring of 
carcinoid heart disease has not yet been evaluated.  
 
1.35 Imaging Modalities for the Assessment of Carcinoid Heart 
Disease 
 
Cardiac imaging plays a key role in the diagnosis and guidance of 
management of cardiac conditions. There are 4 main non-invasive 
imaging modalities in clinical use today; echocardiography, multi-sliced 
cardiac computed tomography (CT), cardiac magnetic resonance imaging 
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(CMR) and nuclear medicine imaging. Carcinoid heart disease is 
amenable to multi-modality assessment. Table 1.2 offers a comparison of 
the imaging modalities.  
 
Echocardiography 
Echocardiography is a relatively cheap, widely available and safe imaging 
modality using ultrasound, which is often the first line imaging technique 
for suspected structural heart disease. It was developed in 1954 by Edler 
and Hertz (76) and is now a fundamental part of daily clinical practice. An 
echo transducer performs the dual role of emitting and transducing 
ultrasound waves (>1.5MHz) using piezoelectric crystals, which convert 
electrical energy to ultrasound waves, and ultrasound back to electrical 
energy.  
 
There are several different modes of echocardiography; two-dimensional 
(2D) imaging, M-mode imaging and Doppler ultrasound. Doppler 
information can be used in different ways; pulsed and continuous wave 
Doppler, colour flow mapping and tissue Doppler imaging. Each mode has 
a specific role in the assessment of cardiac structure and function.  
 
2D imaging provides cross-sectional, real-time images of the heart. By 
manipulating the transducer, different “cuts” can be obtained so that the 
majority of areas of the heart can be assessed. M-mode imaging, the first 
available echo mode, uses a single ultrasound beam to calculate the 
distance of structures from the transducer. This mode has a high frame 
rate, and therefore excellent temporal resolution.  
 
Doppler ultrasound is used to detect the velocity of blood flow through the 
heart (77). Pulsed wave (PW) Doppler uses pulses of ultrasound to 
analyse blood flow at a specific point. It has a high spatial resolution, but 
poor velocity resolution (78). Continuous wave (CW) Doppler, as its 
names suggests, uses continuous ultrasound waves to measure blood 
flow. It overcomes the velocity limitations of PW Doppler by sacrificing 
spatial resolution. It can therefore be used to measure high velocities, but 
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is unable to localise the flow along the ultrasound beam. Colour flow 
mapping is a pictorial representation of PW Doppler data acquired from a 
larger area. It is used to analyse direction and velocity of blood flow, with 
blue representing flow away from the probe, and red illustrating blood flow 
towards the probe. All of these techniques play a role in the assessment of 
carcinoid heart disease. 
 
Echocardiography in the Assessment of Carcinoid Heart Disease 
The consequences of carcinoid heart disease on valve morphology and 
function can be demonstrated relatively easily with 2D transthoracic 
echocardiography (figure 1.3). 2D imaging of each valve, in multiple views, 
is used to assess valve leaflet thickening, mobility and morphology. 
However 2D echocardiography has limited sensitivity and may miss single 
leaflet involvement or diffuse thickening of all valve leaflets without 
significant reduction in leaflet mobility or development of regurgitation, due 
to lower spatial resolution than other cardiac imaging modalities (79).  
 
Valvular stenosis can be identified using PW and CW Doppler, with the 
cursor directed through each valve in multiple echocardiographic views. 
Significant regurgitation is easily identified using a combination of colour 
flow, CW and PW Doppler, and its consequences on right atrial and 
ventricular size and function can be assessed using 2D imaging, M Mode, 
colour and tissue Doppler Imaging.  
 
Imaging from the trans-oesophageal window allows accurate 
measurement of the thickness of the atrio-ventricular valve leaflets and the 
superficial wall layers of both atria (80) and is recommended in the latest 
European Neuroendocrine Tumor Society (ENETs) guidelines for patients 
in whom comprehensive evaluation of the right-sided heart valves is not 
possible via the trans-thoracic approach (13).  
 
It has been suggested that contrast echocardiography should be 
performed in all patients with a diagnosis of carcinoid heart disease (81). 
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This is the modality of choice to determine the presence of intra-cardiac 
shunts and the patency of foramen ovale. Simultaneous venous injection 
of an agitated mixture of saline, blood and air and ultrasound recording of 
2D images enables identification of any communication between the right 
and left heart.  
 
Three-dimensional (3D) echocardiography, whilst being more time-
consuming, can offer supplementary information. It enables an in-depth 
characterisation of valve pathology with an en-face view of the tricuspid 
valve, and has the ability to visualise all three leaflets simultaneously (82-
84). 3D echocardiographic imaging is also able to demonstrate echogenic 
areas consistent with carcinoid deposits (85). Furthermore 3D imaging 
enables a comprehensive assessment of RV geometry, volumes and 
ejection fraction, which is not always possible with a 2D probe (82). The 
use of single-beat 3D echocardiography in RV volume quantification and 
RV functional assessment has recently been evaluated in a small 
population of patients with carcinoid heart disease (86). The authors 
demonstrated that, whilst not as sensitive as CMR, single-beat full-volume 
3D echocardiography is more accurate than conventional 2D 
echocardiography in the assessment of patients with right heart pressure 
and volume overload. 
 
Newer echocardiographic techniques, such as measurement of 
myocardial strain, are not used routinely in the assessment of carcinoid 
heart disease. However there is limited evidence that RV systolic function, 
as assessed by myocardial strain, is reduced in patients with 
neuroendocrine disease independently of valvular involvement (87). 
Mansencal et al. evaluated the prognostic utility of E/E’ (ratio of early 
transmitral flow velocity to early diastolic mitral annulus velocity) in 
carcinoid heart disease (88). The authors demonstrated that E/E’ ratio > 
eight was an independent marker of death, however this was a small 
study, with a limited explanation of the causative reasons for the 
association.  
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A – Apical four chamber view demonstrating severely thickened, retracted tricuspid valve 
with a severely dilated right atrium. 
B – Colour flow across tricuspid valve illustrating severe tricuspid regurgitation with broad 
vena contracta. 
C – Parasternal long axis view of thickened tricuspid valve. 
D – Continuous wave Doppler across tricuspid valve; dense signal demonstrating severe 
tricuspid regurgitation. 
Figure 1.3 Echocardiographic features of carcinoid heart disease 
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Cardiac Computed Tomography 
Imaging the heart using cardiac CT has been anticipated for many years, 
but has been limited by the poor spatial and temporal resolution of 
previous generations of CT scanners (89). However the introduction of 
multi-row detector CT has dramatically improved spatial resolution, 
enabling an in-depth assessment of the right heart chambers and valves, 
which are often difficult to assess using transthoracic echocardiography 
(90). One group has reported using routine staging CT (not cardiac CT) to 
calculate a right ventricle to left ventricle ratio, which can serve as an 
indirect marker of carcinoid heart disease in patients with functional NETs 
(91). However the clinical utility of this is uncertain and CT is not superior 
to transthoracic echocardiography with regard to quantification of 
haemodynamics (valvular regurgitation or pulmonary artery pressure) (92). 
The limited temporal resolution of cardiac CT can also limit appreciation of 
valve motion. Furthermore, exposure to radiation potentially restricts the 
use of cardiac CT, particularly for serial scans. 
 
Cardiac Magnetic Resonance Imaging 
CMR uses high intensity magnetic fields to generate 3D images of the 
heart. This technique is often thought of as the gold standard modality for 
in-depth imaging of the heart. CMR imaging has an important role in the 
assessment of carcinoid heart disease. Its main advantage is the accurate 
and reproducible assessment of the right heart, which can be difficult 
using echocardiography alone (93). The problem of sub-optimal 
visualisation of the right-sided heart valves, particularly the pulmonary 
valve, can be overcome with MR imaging which provides precise 
functional and anatomical information, allowing accurate quantification of 
regurgitant volumes (94,95) (figure 1.4).  
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A) Dilated right atrium and ventricle in four chamber view (systole). Thickened, fixed and 
retracted tricuspid valve (arrows).  
B) Thickened, retracted pulmonary valve leaflets (arrow).  
C) Phase contrast flow map demonstrating severe tricuspid regurgitation (arrow).  
Figure 1.4 Cine CMR (83) 
 
In addition, CMR enables identification of extension into extra-cardiac 
structures, an aspect less well appreciated by echocardiography (83). The 
administration of a Gadolinium-based contrast agent can identify both 
myocardial metastases (59) and endocardial plaque deposition (96). CMR 
imaging is recommended in ENETS guidelines for evaluation of the 
pulmonary valve, for identification of cardiac metastases and for 
assessment of RV function (13). 
 
Nuclear Medical Imaging 
Single photon emission computed tomography (SPECT) uses a gamma-
emitting radioisotope to assess myocardial blood flow at rest and during 
stress (diseased myocardium has reduced blood flow compared to normal 
myocardium). Positron emission tomography (PET) using a radionuclide 
tracer can be used to identify metastatic spread of carcinoid tumours 
(figure 1.5) and has a role in the identification of cardiac metastases, 
which occur in approximately four percent of patients with carcinoid 
syndrome (83). A variety of tracers have been utilised including 18F-
dihydroxy-phenyl-alanine (97) and octreotide labelled with Gallium68 and 
Indium111 (45,83).  
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Figure 1.5 Gallium68 octreotide PET demonstrating avid focal uptake of 
tracer in the region of the metastatic carcinoid tumour within the heart (83). 
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Variable 2D Transthoracic Echo 3D Transthoracic Echo Trans-oesophageal Echo Dual source multi-slice CT Cardiac MRI 
Spatial resolution ++ (79) + (98) +++ ++++ (99) +++ (100) 
Temporal resolution ++++ + +++ ++ +++ (101) 
Approximate scan time 
(minutes) 40 – 45 (102) 
45-60; Full 2D exam + 
focused 3D (103) 45 - 60 (104) 15 (105) 15 (106) 
Average cost per study 
(£) 
142(107) 292 (107) 292 (107) 320 (contrast) (108) 673 (109) 
Availability 12,000 scans per million population in 2006 (110) Now widely available 
3500 scans per million population 
in 2006 (110) 
45 centres in the UK in 2011 
(111) 
60 centres in the UK in 
2011(112) 
Radiation None None None 1.5 – 5 mSv (113) None 
Limitations None known Time required for reconstruction of images 
Oro-pharangeal injury, 
oesophageal 
laceration/perforation, gastric 
perforation, airway compromise. 
Contraindicated in oesophageal 
pathology, recent GI bleed, severe 
cervical arthritis (114) 
Anaphylactoid reaction, urticaria, 
contrast medium extravasation, 
contrast nephropathy, skin 
reaction (115) 
 
Relatively contraindicated in 
CKD and pregnancy 
As for CT plus: 
Nephrogenic systemic 
fibrosis (115) 
 
Contraindicated in 
patients with intracranial 
or intraocular metal work 
Clinical validation in 
assessment of the right 
heart 
Least accurate technique (116) Well-validated (82) In small studies (80,117) Mainly validated for assessment of pulmonary hypertension (118) 
Gold standard, most 
accurate technique 
(119) 
 
Value in serial studies 
 
Well established (4,49,52,56,120) Not validated Limited due to invasive nature Not validated Limited due to cost 
Evidence of correlation 
with other markers of 
carcinoid heart disease 
NTproBNP(53), Urinary 5HIAA 
(49), Chromogranin A (55), 
Histopathological examination of 
excised valves (83) 
Histopathological 
examination of excised 
valves (83,121) 
Histopathological examination of 
excised valves (83,121) No data identified No data identified 
BSE – British Society of Echocardiography, GI – Gastrointestinal, CKD – Chronic kidney disease 
 
Table 1.2 Comparison of imaging modalities for the assessment of carcinoid heart disease  
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1.36 Echocardiographic Scoring Systems for Carcinoid Heart 
Disease 
 
Objective, repeated assessment of patients with carcinoid heart disease is 
imperative to ensure that progression of disease is identified and acted 
upon at an early stage. Several scoring systems for the echocardiographic 
assessment of carcinoid heart disease have been developed (table 1.3), 
but used with limited evaluation of their validity and utility. Consequently 
there is uncertainty surrounding the clinical relevance of these scoring 
systems. 
 
Moller et al. performed a retrospective review of 103 patients with 
carcinoid heart disease and semi-quantitatively assessed their 
echocardiographic findings (122). A score was calculated for each patient, 
with a potential maximum of 20 points. Tricuspid and pulmonary anatomy 
and regurgitation were graded on a four-point scale, based on leaflet 
motion, thickening and retraction (with 0 denoting normal, 1 thickened with 
reduced mobility, 2 thickened with severe immobility, and 3 thickened and 
fixed). Valvular regurgitation was assessed semi-quantitatively on a scale 
of 0 (trivial or no regurgitation) to 3 (severe regurgitation). This was based 
on visual interpretation, and the width, size and/or ratio of the maximal 
regurgitant jet. A score of 0 to 3 was also used to assess RV size and 
function, with 0 representing normality and 3 representing severely 
enlarged or impaired. Scores were assigned for the presence (1) or 
absence (0) of diastolic forward flow in the pulmonary artery and systolic 
flow reversal in hepatic veins. 
 
Bhattacharyya et al. (53) developed a scoring system, with a potential 15 
points attributed to each valve, in addition to assessment of RV size and 
function, leading to a maximum of 66 points. Each valve was graded 0-3 
for leaflet thickness, mobility and morphology, and valvular stenosis and 
regurgitation (see chapter two, table 2.2 for more details). RV function and 
size were also graded 0-3. There was no agreed threshold as to what 
 38 
defined carcinoid heart disease. Two hundred patients were recruited to 
this observational cohort study, with 39 patients having evidence of 
carcinoid heart disease. The carcinoid heart disease scores obtained from 
this scoring system correlated highly with NTproBNP (r=0.81, 95% CI 
0.67-0.89, P< 0.0001).  
 
A third system was devised by Denney et al. for use in their prospective 
study of 23 patients with carcinoid syndrome, culminating in 126 
echocardiographic studies (49). The score combined 2D and Doppler 
criteria to assess tricuspid valve anatomy (leaflet thickness and mobility) 
and tricuspid regurgitation (TR) (TR area/right atrial area), along with 
pulmonary regurgitation (PR) (PR neck width/pulmonary valve (PV) 
annular diameter) and stenosis (peak PV systolic velocity), producing a 
maximum score of 14.  
 
An alternative scoring system was created by Mansencal et al. (123), used 
initially for their prospective study of 41 patients with carcinoid syndrome 
and then adapted in 2010 (56) to incorporate left heart assessment. A 
maximum score of 20 was achievable for right-sided disease, based upon 
RV size, tricuspid and pulmonary valvular anatomy, regurgitation and 
stenosis. Right-sided carcinoid heart disease was defined as valvular 
injury concomitant with regurgitation or stenosis, or RV enlargement with 
endocardial thickening or evidence of a metastatic carcinoid tumour to the 
heart. Patients without evidence of valvular immobility were not considered 
to have carcinoid heart disease. The adapted score awarded a further 10 
points for left sided disease, based upon mitral and aortic valve anatomy 
and regurgitation.  
 
Westberg et al. devised a score for use in their study of 52 patients with 
carcinoid syndrome who all underwent echocardiography (50). The 
tricuspid and pulmonary valves were scored for anatomy and 
regurgitation, but only the tricuspid valve was included in the overall score. 
A score of one or more was regarded as pathological. This score had a 
significant effect on survival (30% 5-year survival rate for those with a 
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score > 4 v 75% in patients with a normal score). This scoring system was 
adapted and used by Zuetenhorst et al. in 2003.  
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 Bhattacharyya 
(53) 
Denney 
(49) 
Mansencal 
(123) 
Moller 
(122) 
Westberg 
(50) 
Year 
 
 
2008 1998 2010 2003 2001 
No. of patients 200 23 80 71 52 
No. of echo studies 200 126 ≥ 160 174 52 
Population 
characteristics 
Midgut carcinoid 
with syndrome 
Carcinoid 
tumour with 
syndrome 
Midgut carcinoid 
with syndrome 
Carcinoid tumour 
with syndrome 
Midgut carcinoid with 
syndrome 
Age 
 
64 +/- 13  59 +/- 12  62 +/- 12  56 (45 – 67) ¸ 61 +/- 4  
% of patients with CHD 19.5% 35% 33% (right) 8% (left) 50% 65% 
No. of valves assessed 4 2 4 2 1 
Maximum score 66 14 30 20 8 
Right heart assessment Yes No Yes Yes No 
Weighting for right heart 
pathology No No Yes No No 
Left heart assessment Yes No Yes No No 
Clinical correlates NTproBNP Urinary 5HIAA Chromogranin A Urinary 5HIAA Urinary 5HIAA 
Urinary 5HIAA, 5-year 
survival 
Assessment of CHD 
progression (serial echo) No Yes Yes Yes No 
Other studies using 
same score 
Bhattacharyya et 
al. (4, 54) None identified 
Mansencal et al. 
(56,92) 
Bernheim et al. 
(128) Zuetenhorst et al. (52) 
CHD carcinoid heart disease,  Mean and standard deviation, ¸ Median and interquartile range from time of diagnosis of carcinoid syndrome in those with 
CHD at baseline 
Table 1.3 Echocardiographic scoring systems for carcinoid heart disease  
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1.37 Management of Carcinoid Heart Disease 
 
Carcinoid heart disease is a rare, complex disease, and should be 
managed in a specialist centre, with multi-disciplinary team (MDT) input 
from oncologists, cardiologists, endocrinologists, gastroenterologists, 
palliative care physicians, radiologists, nuclear medicine physicians, 
pathologists and surgeons (colorectal, hepatobiliary and cardiothoracic) 
(47,125). The management of NETs is discussed earlier in this chapter, 
section 1.21 and 1.22. 
 
Screening for Carcinoid Heart Disease 
Screening for carcinoid heart disease is a vital aspect of the multi-
disciplinary management of patients with NETs. As for all conditions, 
management should be evidence-based and in line with current best 
accepted practice. However, there is considerable discordance in the 
recommendations for screening among international guidelines (table 1.4). 
There is a lack of clarity regarding who to screen, how frequently to screen 
and how best to utilise echocardiography.  
 
The United Kingdom and Ireland Neuroendocrine Tumour Society (UKI 
NETs) guideline recommends a large cohort of patients to be screened, 
with NTproBNP used as a “gatekeeper” for echocardiography. In contrast, 
the European Neuroendocrine Tumor Society (ENETS) guideline 
advocates biochemical criteria rather than clinical or radiological criteria as 
the trigger to initiate cardiac screening. The North America 
Neuroendocrine Tumor Society (NANETS) guideline lacks detail on who or 
how frequently patients should be screened, but does concur with the UK 
guideline with regard to the use of NTproBNP. 
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Guideline Cohort to be screened 
Screening 
frequency/interval 
Suggested 
biomarkers 
Use of 
echocardiography 
UKI NETS: Guideline for the management of 
gastroenteropancreatic (including carcinoid) 
tumours (NETs); 2011 (13) 
Midgut NETS (with & 
without hepatic 
metastases) and all with 
carcinoid syndrome 
Not stated NTproBNP 
Patients with 
NTproBNP 
>260pg/ml 
ENETS: Consensus Guidelines for the 
Management of Patients with Neuroendocrine 
Neoplasms from the Jejuno-Ileum and the 
Appendix Including Goblet Cell Carcinomas; 
2012  (126) 
Functioning NET (elevated 
CgA/5HIAA) with carcinoid 
syndrome 
“Regular basis” – 
suggested interval 
not stated 
CgA 
5HIAA 
NTproBNP 
Symptomatic 
patients with 
elevated CgA & 
5HIAA 
NANETS: Consensus Guidelines for the 
Diagnosis of Neuroendocrine Tumor; 2010  
(127) 
Not stated Not stated NTproBNP 
Patients with raised 
NTproBNP (no cut-
off suggested) 
UKI NETS - United Kingdom and Ireland Neuroendocrine Tumour Society, ENETS - European Neuroendocrine Tumor Society, NANETS - North America 
Neuroendocrine Tumor Society 
 
Table 1.4 International guidelines for screening for carcinoid heart disease
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Medical Management of Carcinoid Heart Disease 
Although there is no current evidence that SSAs reduce the risk of 
developing carcinoid heart disease, or delay progression of established 
cardiac involvement, there is a belief that these drugs may be beneficial. 
Serotonin plays a pivotal role in the pathogenesis of carcinoid heart 
disease and therefore it is plausible that SSAs, through their reduction of 
serotonin levels, may be advantageous. However it is unlikely there will 
ever be a randomised controlled trial investigating the progression of 
carcinoid heart disease with SSAs as they are so well-established in the 
treatment of NETs, it would be unethical to withhold them. 
 
At present, there is no evidence to suggest that interventions such as 
hepatic de-arterialisation or systemic chemotherapy have a beneficial 
effect on the progression of valvular disease (122). Bacterial endocarditis 
prophylaxis is not indicated in patients with carcinoid heart disease  (128). 
General measures to treat right heart failure, such as the use of diuretics 
and fluid and salt restriction may improve symptoms of oedema. However 
these measures can be deleterious in advanced RV failure due to 
depletion of intravascular volume further reducing cardiac output, leading 
to fatigue and breathlessness  (124). Digoxin is believed to improve RV 
contractility but there are limited data on its use in patients with pure right 
heart failure (129).  
 
Surgical Management of Carcinoid Heart Disease 
The first heart valve surgery for carcinoid heart disease was conducted in 
1963 (130). Valve surgery is the only definitive treatment option for those 
with severe carcinoid heart disease; improving both quality of life and 
overall survival (120,131). Indications for valve surgery include 
progressive RV failure or dilatation, heart failure symptoms not responding 
to medical therapy or the need for hepatic resection (132,133). It is 
generally accepted that patients with significant carcinoid heart disease 
are precluded from hepatic resection due to the risk of problematic 
haemorrhage secondary to raised right atrial pressure and a pulsatile liver. 
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However a recent case report described a successful hepatectomy using 
venovenous bypass in a patient with severe carcinoid heart disease who 
then went on to have successful cardiac surgery (134). 
 
Valve repair, although preferable, is not usually possible due to the degree 
of leaflet restriction causing post-repair stenosis (57). The decision 
regarding which valve prosthesis to implant is complex and has to be 
made on an individual case-by-case basis. Mechanical prostheses were 
previously recommended because of fear of premature degeneration of 
the bioprosthesis due to active carcinoid disease (25). However 
bioprosthesis implantation, without valve degeneration or dysfunction, has 
been described in a patient who was followed up for over three years 
(135). A recent small case series described premature re-stenosis of a 
stentless bioprosthesis in the pulmonary position, necessitating trans-
catheter valve replacement (136). However bioprosthetic valves have the 
advantage of not requiring long-term anticoagulation, making subsequent 
surgical procedures (e.g. hepatic artery embolisation or cytoreductive 
surgery) less complicated (137).  
 
The first cardiac valve surgery for carcinoid heart disease had an 
unacceptably high peri-operative mortality rate of 20-50% (43). Peri-
operative mortality rates following valve replacement range widely in the 
literature but have improved in recent years (table 1.5). A review of ten 
papers on the prognosis of patients with carcinoid heart disease after 
valvular surgery demonstrated an average 30-day mortality of 17% (range 
1-63%) (138). This included a total of 285 patients undergoing valve 
surgery with data collected between 1985 and 2012. Nine papers were 
retrospective studies and one was a case series, with varying periods of 
follow-up. Survival data varied between the studies with only a minority of 
studies reporting one and two year survival. Most of the deaths were due 
to right heart failure, with carcinoid crisis, infection, valve thrombosis and 
advancing metastases accounting for the remainder. The improved 
survival of patients with carcinoid heart disease in recent years may reflect 
the increasing surgical experience in this field, and better peri-operative 
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management of the patient with octreotide.  
 
More recently, a retrospective analysis of short and long term outcomes in 
195 patients with carcinoid heart disease undergoing valvular surgery 
between 1985 and 2012 demonstrated a decrease in operative mortality 
from more than 20% to less than five percent  (125). The authors 
attributed this improvement to a combination of factors; improved patient 
selection, involvement of a MDT, advances in the management of the 
underlying malignancy and also improvements in surgical technique. 
 
 
Author; year, type of study Number of patients 
30 day peri-
operative 
mortality 
Long term 
survival 
Connolly; 1995 
Observational cohort study  (139) 26 35% 40% 2 year survival 
Robiolio; 1995 
Retrospective study  (140) 8 63% 38% 2 year survival 
Castillo; 2008  
Retrospective study  (141) 11 18% 
100% at median 21 
months (4-75) 
Bhattacharyya; 2011 
Observational cohort study (137) 22 18% 
56% 1 year survival 
44% 2 year survival 
Mokhles; 2012 
Retrospective study (131) 19 5% 
71% 1 year survival 
43% 5 year survival 
Connolly; 2015 
Retrospective study  (125) 195 
10% overall 
6% after 2000 
69% 1 year survival 
35% 5 year survival 
24% 10 year 
survival 
Edwards; 2016 
Retrospective study  (142) 32 13% 
75% 1 year survival 
69% 2 year survival 
 
Table 1.5 Surgical outcomes for valve replacement in carcinoid heart 
disease 
 
Carcinoid crisis is characterised by a potentially life-threatening 
combination of flushing, hypotension and bronchospasm  (143) which can 
be precipitated by surgery (particularly direct manipulation of the tumour) 
and the administration of catecholamines and histamine-releasing drugs 
(57). Due to the risk of this and low output cardiac syndrome secondary to 
RV failure, all patients undergoing valve surgery require peri-operative 
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infusion of octreotide  (141). Octreotide inhibits the secretion of vasoactive 
peptides such as bradykinin and serotonin, thereby controlling carcinoid 
symptoms  (144,145).  
 
Balloon valvuloplasty for pulmonary stenosis is an option for patients with 
a high operative risk, or in those considered unsuitable for valve surgery 
(146,147). This technique has also been described in patients presenting 
with failure of a pulmonary biological xenograft, with successful 
implantation of a balloon-expandable transcatheter heart valve (148). 
However there is limited evidence for this technique (149) and recurrence 
of obstruction has been reported (150). Transcatheter caval valve 
implantation is an alternative option for patients who are considered to be 
inoperable. This technique has been described in patients with severe 
valvular disease, with substantial symptomatic improvement obtained from 
the intervention (151,152). However, there are no long term data on the 
use of caval valve implantation.  
 
1.38 Progression of Carcinoid Heart Disease 
 
The progression of carcinoid heart disease is not wholly understood, with 
multiple factors likely to be implicated in its aetiology. Serotonin levels are 
higher in those with cardiac involvement, but reduction in these levels is 
not associated with regression of carcinoid heart disease (49,50). 
Furthermore, more than 50% of patients with increased serotonin do not 
develop carcinoid heart disease, suggesting that there are other unknown 
factors involved in the pathogenesis of the disease (153).  
 
To date few authors have reported factors associated with the progression 
of carcinoid heart disease or defined which measure of progression is 
most useful. In a study of 71 patients with carcinoid syndrome and 32 
patients referred directly for valve replacement, Moller et al. demonstrated 
that progression of cardiac involvement, in 35% of patients, was 
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associated with higher urinary 5HIAA levels and was more likely in 
patients who had received chemotherapy (122). The authors noted that 
the relationship between chemotherapy and progression of carcinoid heart 
disease may be explained by the fact that those receiving chemotherapy 
were more likely to have more aggressive underlying disease.  
 
More recently, Bhattacharyya et al. demonstrated a 17.5% progression 
rate in patients with carcinoid syndrome over a median follow-up duration 
of 29 months (4). Independent predictors of the development or 
progression of carcinoid heart disease were urinary 5HIAA levels > 300 
umol/24 hours and three or more daily episodes of facial flushing. In both 
of these studies, carcinoid heart disease progression was defined as a 
25% or more deterioration in the echocardiographic score of the patient.  
 
A third study, which defined progression of carcinoid heart disease as a 
score increase of greater than twice the standard deviation of the mean 
intra-observer variability also demonstrated an association between post-
therapy 5HIAA levels and the progression of carcinoid heart disease 
although the study only included 23 patients (49).  
 
An additional study investigated the rate of progression of carcinoid heart 
disease but did not investigate potential factors associated with this (56). 
The prospective study of 80 patients with carcinoid syndrome, followed up 
for 26 months, demonstrated a progression rate of 20% with a further 20% 
of patients developing carcinoid heart disease during the study period but 
the authors did not clearly define what was meant by “progression” of 
carcinoid heart disease. 
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1.39 Prognosis of Carcinoid Heart Disease 
 
Carcinoid heart disease has a significant impact on patient morbidity and 
mortality. It is associated with a relatively poor clinical outcome, and whilst 
prognosis has improved in recent decades, average survival is still only 
around four years (120). Carcinoid heart disease with NYHA functional 
class III or IV symptoms has a particularly bleak prognosis with a median 
survival of 11 months  (139). In a cohort of patients with carcinoid 
syndrome, Pellikka et al. demonstrated a mean survival of 1.6 years in 
those with cardiac involvement, compared to 4.6 years in those without 
(42). Westberg et al. found that carcinoid heart disease was the main 
predictor of prognosis in patients with midgut neuroendocrine disease 
(50). Westberg et al. demonstrated a risk ratio of 2.55 for each increasing 
grade of tricuspid regurgitation (0-4, none, mild, moderate, severe), which 
translates to a more than tenfold increased risk of death for patients with 
severe tricuspid regurgitation compared to those with no tricuspid 
regurgitation. The commonest cause of death in patients with carcinoid 
heart disease is right-sided heart failure (around 50%) (154) with tumour 
progression responsible for around 45% of deaths.  
 
Moller et al. postulated that the recent improvement in survival from 
carcinoid heart disease may be related to increasing valve surgery 
interventions for patients with the disease (120). Furthermore, the 
increasing use of SSAs to lower plasma serotonin concentrations may 
also have contributed to the improved survival from the disease however 
there is a lack of contemporary survival data from patients diagnosed 
within the last decade to confirm this assumption. 
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1.40 Future Perspectives 
 
There are still many uncertainties surrounding the pathophysiology and 
management of carcinoid heart disease. Although high circulating levels of 
serotonin are necessary for the development of carcinoid heart disease, 
not all patients with raised serotonin develop the disease and therefore it 
is probable that there are other contributory factors, including 
environmental, genetic and inflammatory factors that are yet unknown. It is 
not known why approximately 20% of patients with carcinoid syndrome 
develop valvular pathology, or what protects the other 80% of patients. 
 
With regard to the management of carcinoid heart disease, further 
investigation into the progression of carcinoid heart disease is required, 
with particular emphasis on the role of SSAs.  
 
The need for cohesive, evidence-based guidelines for carcinoid heart 
disease has been recognised by a panel of experts in the UK, and a 
consensus guideline for the management of the condition is in the process 
of being written. This will enable health care professionals managing 
patients with NETs to provide the best possible standard of care.  
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2.1 Patient Recruitment 
 
2.11 Patient Source  
 
Patients with non-pancreatic NETs were recruited from hospitals within the 
catchment area of four tertiary referral NET centres of excellence. The four 
centres were University Hospital Aintree National Health Service (NHS) 
Trust, Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS 
Trust, Liverpool; The Christie Hospital NHS Trust, Manchester; and St 
James’s University Hospital, Leeds. These hospitals have a collective 
catchment area of over 9 million patients (155-158).  
  
The research contained within this thesis is part of an ongoing clinical 
research programme, supported by the Liverpool Neuroendocrine Tumour 
Group. Prior to the author’s involvement in the programme, 89 patients 
were already recruited. Subsequently the author recruited a further 179 
patients during the period December 2011 - September 2013.  
 
The author personally attended the tertiary centres, and their feeder 
hospitals, to prospectively recruit, interview, examine, perform 
echocardiography, and obtain blood from patients. Patients were either 
recruited at the time of their appointment in the NET outpatient clinic, or for 
those patients without an outpatient appointment, were identified by their 
NET consultant and then invited via letter to participate in the study. 
 
The studies conformed to the Declaration of Helsinki and ethical approval 
was obtained from Liverpool Research Ethics Committee (reference 
09/H1005/40). All patients gave written informed consent.  
 
2.12 Inclusion & Exclusion Criteria 
 
The inclusion criteria were diagnosis of a non-pancreatic NET, with liver 
metastases and/or carcinoid syndrome (episodes of cutaneous flushing, 
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diarrhoea or wheezing) by a specialist neuroendocrine team and clear 
visualisation of all four valves at echocardiography to enable 
comprehensive echocardiographic assessment.  
 
The exclusion criteria were presence of a prosthetic heart valve or 
inadequate visualisation of valves such that an echocardiographic score 
could not be determined.  
 
2.13 NET Diagnosis 
 
Diagnosis of a NET was based on histological evidence where available, 
with characteristic immunostaining for Chromogranin A (CgA) and 
synaptophysin. In patients with unknown primary tumour sites, metastatic 
tissue was immunostained for CDX2, cytokeratin 20, thyroid transcription 
factor-1 and/or cytokeratin 7 to enable differentiation between 
gastrointestinal or bronchial primary sites. Histological grading was based 
on the Ki67 proliferative index (antigen Ki-67 is a nuclear protein that is a 
marker of cellular proliferation). Where histological evidence was not 
available, the diagnosis was made on the basis of characteristic 
appearances on cross-sectional (CT and/or MR) and functional (111In-
Octreotide scan) imaging. No patients with inherited cancer syndromes 
were included in the study.  
 
2.14 Clinical History and Measurements  
 
All patient records were reviewed and the following information obtained: 
histological diagnosis, tumour proliferative index, duration of disease, 
primary tumour site, presence or absence and size of hepatic metastases, 
presence of carcinoid syndrome, use of proton pump inhibitor therapy and 
therapeutic interventions. In addition, NYHA category was ascertained by 
verbally asking the patient the following questions:  
 
1. Are you able to walk up hills without restriction?  
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2. Are you more short of breath than expected walking up hills or stairs?  
3. Are you short of breath performing basic tasks, for example, getting 
washed or dressed?  
4. Are you short of breath watching television or sitting still?  
 
At the time of echocardiography and blood sampling, the patient’s height 
and weight were ascertained. Body mass was measured, without shoes, 
to the nearest 0.5kg, using calibrated electrical digital scales (Seca, 
Germany). Height was measured with a stadiometer to the nearest 0.5 cm 
(Seca, Birmingham, UK). Body mass index (BMI) was calculated as weight 
in kilograms divided by height in metres, squared. 
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2.2 Biochemistry 
 
Venous (non-fasting) blood samples were taken on the day of baseline 
echocardiography and at the time of subsequent echocardiograms. 
Plasma and serum were separated by centrifugation (3,500 rpm) and 
stored at -80oC until further analysis. All biochemical measurements were 
made without knowledge of the clinical status of the patient. The 
concentration of the following biomarkers was determined: 
 
Serum Chromogranin A (CgA): 
A synthetic porcine pancreastatin, Peninsula, CA, USA, comparable to the 
Cisbio and Dako assays (159), measured at Hammersmith Hospital, 
Imperial College, London. The upper limit of normal is 3 ng/ml with an 
inter-assay variation of 22%. The intra-assay variation is 12.3% at 12.4 
pmol/l (160).  
 
Serum Chromogranin B (CgB): 
A Gawk immunoassay, Cambridge Research Biochemical, Cambridge, 
UK, measured at Hammersmith Hospital, Imperial College, London. The 
upper limit of normal is 12 ng/ml with an inter-assay variation of 11%. The 
intra-assay variation is 6.8% at 134 pmol/l (160).  
 
Serum N-terminal Pro-Brain Natriuretic Peptide (NTproBNP): 
Electrochemiluminescence technology on the fully automatic Elecsys® 
analyser, Roche Diagnostics, measured at University Hospital Aintree 
NHS Trust. The upper limit of normal is 146 ng/L with an intra-assay 
variation below 4% and inter-assay variation below 5% at concentrations 
above 70 pg/ml (161).  
  
Plasma 5-Hydroxyindoleacetic Acid (5HIAA): 
Liquid Chromotography–Mass Spectrometry/Mass Spectrometry 
(LCMS/MS) method comparable to that used by Tellez (67) with 
QuanLynxTM software (Waters, Watford, UK), measured at University 
Hospital of South Manchester NHS Trust. The upper limit of normal is 118 
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nmol/L with an inter-assay coefficient of variation of 2.6 – 9.8% and an 
intra-assay variation of 2-4.7%) (162). 
 
Plasma Neurokinin A (NkA): 
An in-house radioimmunoassay developed and measured by the Regional 
Regulatory Peptide Laboratory, Royal Victoria Hospital, Belfast. The upper 
limit of normal is 20 ng/L with an inter-assay co-efficient of variation of 6.4-
8.4% and an intra-assay variation of 1.6-4.6% (71).  
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2.3 Transthoracic Echocardiography 
 
2.31 Data Acquisition 
 
Transthoracic echocardiography was performed using a General Electric 
(GE) Vivid 7 or Vivid Q machine (2.5 MHz phased array transducer, 
Horten, Norway) by one of two experienced operators (CW 89 
echocardiographic studies, RD 179 echocardiographic studies). Patients 
were positioned semi-supine, in the left lateral position. Video loops were 
acquired triggered to the ECG (3 cardiac cycles) in end-expiration. 
 
The tricuspid valve was visualised from the parasternal long axis, (with a 
downward tilt for the RV inflow view), the parasternal short axis, the apical 
four chamber and the subcostal view. The pulmonary valve was visualised 
from the parasternal long axis, (with an upward tilt for the RV outflow view) 
and the parasternal short axis. The mitral valve was visualised from the 
parasternal long and short axes, the apical four chamber, apical two 
chamber and apical long axis views. The aortic valve was visualised from 
the parasternal long and short axes, the apical five chamber and apical 
long axis views.  
 
M-mode, with the cursor aligned with the leaflet tips, was used to assess 
aortic and mitral valve leaflet motion in the parasternal long axis view. 
Colour flow mapping Doppler was utilised with the sector positioned over 
each valve to assess turbulent blood flow and regurgitant jets. PW Doppler 
was used to assess trans-mitral and left ventricular outflow tract (LVOT) 
flow. CW Doppler was used to assess blood flow across all four valves. 
Care was taken to optimise all images in terms of time-gain compensation, 
depth, focus and sector width, thereby improving frame rate. 
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2.32 Data Analysis 
 
All echocardiographic studies, (regardless of who obtained the images) 
were analysed off line using Echopac (V9.01, GE, Horten, Norway) by the 
author. A diagnosis of carcinoid heart disease was decided by the 
operator based on consensus guidelines (81). Carcinoid heart disease 
was defined as thickening and reduced excursion of valvular leaflets, 
cusps or chordae, with subsequent valvular regurgitation and/or stenosis 
(53). 
 
In all chapters, other than chapter five, the Bhattacharyya score (table 2.1) 
(53) was used to quantify carcinoid heart disease and therefore valvular 
disease was quantified using the same methods that were used in their 
original paper. 
 
Characteristic Degree of severity and score assigned 
Leaflet 
thickening 
< 3mm 
0 
≥ 3 - < 4mm 
1 
≥ 4 - < 5mm 
2 
≥ 5 mm 
3 
Leaflet mobility 
Normal 
0 
Mildly reduced 
excursion 
1 
Moderately 
reduced 
excursion 
2 
Severely reduced 
excursion/fixed 
leaflets 
3 
Leaflet 
morphology 
Normal 
0 
Straightened & 
stiffened valve 
leaflets 
1 
Mild leaflet 
retraction 
2 
Moderate/severe 
retraction 
3 
Valvular 
stenosis 
Normal 
0 
Mild 
1 
Moderate 
2 
Severe 
3 
Valvular 
regurgitation 
Normal 
0 
Mild 
1 
Moderate 
2 
Severe 
3 
Right 
ventricular 
diameter 
Normal 
0 
Mildly 
enlarged 
1 
Moderately 
enlarged 
2 
Severely enlarged 
3 
Right 
ventricular 
function 
Normal 
0 
Mildly impaired 
1 
Moderately 
impaired 
2 
Severely impaired 
3 
Table 2.1 Carcinoid heart disease scoring system (53) 
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Valve stenosis was quantified according to European and American 
Society of Cardiology Recommendations (163) and using the same 
quantification used in Bhattacharyya’s original paper (53). Tricuspid 
stenosis was quantified according to the mean gradient across the valve 
(mild 1-5mmHg, moderate 6-8mmHg, severe >8mmHg). The mean 
gradient was calculated by tracing the forward flow Doppler spectrum in 
either the parasternal long axis RV inflow view, or in the apical four 
chamber view.  
 
Pulmonary stenosis was quantified according to the peak gradient across 
the valve (mild <25mmHg, moderate 25-50mmHg and severe >50mmHg). 
The peak gradient was calculated using CW Doppler, lined up parallel to 
the flow across the valve using colour flow mapping in the parasternal 
short axis view or parasternal long axis RV outflow view.  
 
Mitral stenosis was quantified according to the mean gradient across the 
valve (mild <5mmHg and severe >10mmHg). Valve area was calculated 
with an area >1.5cm2 consistent with mild stenosis and <1cm2 consistent 
with severe stenosis. Pulmonary artery systolic pressure was calculated, 
but used only as a supportive sign rather than a surrogate marker. 
 
Aortic stenosis was quantified using CW Doppler according to the mean 
gradient across the valve (<25mmHg mild, >40mmHg severe), the peak jet 
velocity across the valve (<3m/sec mild, >4 m/sec severe) and the valve 
area as assessed by the continuity equation (164) (>1.5cm2 mild, <1cm2 
severe).  
 
Valve regurgitation was quantified according to the American Society of 
Echocardiography Guidelines (165). Tricuspid regurgitation was assessed 
using a composite of Doppler and 2D imaging in the parasternal long axis 
RV inflow view, the parasternal short axis view and the apical four 
chamber view. Vena contracta width was measured using colour flow 
Doppler, with a width >0.7cm considered indicative of severe tricuspid 
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regurgitation. CW Doppler was used to record the jet velocity across the 
tricuspid valve. The contour and density of the jet was assessed to aid in 
the distinction between mild, moderate and severe regurgitation (mild: soft, 
parabolic shape, moderate: dense jet with variable contour and severe: 
dense spectral recording, with a triangular, early peaking of the velocity). 
The regurgitant jet area was assessed using colour flow Doppler. An area 
<5cm2 was considered mild, moderate 5-10cm2 and severe >10cm2. 
Where possible, pulsed wave Doppler interrogation of the hepatic veins 
was used to detect the presence or absence of systolic flow reversal, its 
presence indicating severe tricuspid regurgitation. The size of the right 
atrium, RV and inferior vena cava was also taken into account when 
making the distinction between mild, moderate and severe regurgitation 
(usually normal in mild regurgitation and usually dilated in severe 
regurgitation).  
 
Pulmonary regurgitation was assessed in the parasternal RV outflow view 
and the parasternal short axis view using a combination of Doppler and 2D 
imaging. Colour flow Doppler was used to identify pulmonary regurgitant 
jets. The length and area of the jet was determined (whilst accepting that 
both of these measurements are affected to some extent by the pressure 
difference between the pulmonary artery and the RV). The vena contracta 
was determined where possible. CW Doppler through the pulmonary valve 
was used to assess the density of the pulmonary regurgitant signal. A 
rapid deceleration rate was considered consistent with severe 
regurgitation, however this is influenced by several other factors such as 
RV diastolic properties and filling pressures. The size of the RV was also 
taken into consideration when grading the severity of the pulmonary 
regurgitation (normal size virtually excludes significant regurgitation).  
 
Mitral regurgitation was assessed using 2D imaging, and Doppler in the 
parasternal long axis view and the apical views. The size of the regurgitant 
jet was estimated using colour flow Doppler with mild classed as <4cm2 or 
<20% of left atrial area and severe classed as >10cm2 or >40% of left 
atrial area or any wall-hugging jet which swirls into the left atrium. Colour 
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flow Doppler was also used to identify the vena contracta, with a width 
<0.3cm classed as mild and a width >0.7cm classed as severe. Where 
possible, the effective regurgitant orifice area (EROA) was measured in 
the apical four chamber view. An EROA <0.2cm2 was classed as mild and 
>0.4cm2 was classed as severe. CW Doppler through the mitral valve was 
used in order to assess the shape and density of the signal. An early 
peaking, triangular contour with a dense signal was considered suggestive 
of severe regurgitation. PW Doppler at the mitral leaflet tips, was used to 
assess trans-mitral flow. An E velocity higher than during atrial contraction 
and >1.2m/sec was considered suggestive of severe regurgitation. 
Pulmonary venous flow was assessed where possible to aid identification 
of severe mitral regurgitation (systolic flow reversal). 
 
Aortic regurgitation was assessed in the parasternal long axis, apical five 
chamber and apical long axis view. Using colour flow Doppler the three 
components of regurgitant flow were all assessed where possible. The 
regurgitant jet size was assessed via measurement of the jet width in 
proportion to the LVOT width in the parasternal long axis view (<25% mild, 
>65% severe). Vena contracta was measured in the parasternal long axis 
view with a width of <0.3cm classed as mild and a width of >0.6cm 
classed as severe. In the apical five chamber view the EROA was 
calculated where possible (mild <0.1cm2 and severe >0.3cm2). CW 
Doppler through the aortic valve enabled EROA calculation, assessment 
of the shape and density of the Doppler signal and deceleration rate 
(pressure half time). A pressure half time <200msec was considered 
severe with >500msec considered mild. 
 
RV size and function were assessed according to the American Society of 
Echocardiography guidelines (166). RV dimensions were measured at 
end-diastole from a RV-focused apical four chamber view. Basal and mid-
ventricle dimensions were recorded, along with a longitudinal 
measurement. The RVOT was measured in the parasternal short axis 
view, above the aortic valve (RVOT1) and just proximal to the pulmonary 
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valve (RVOT2). Quantification into mild, moderate and severe dilatation of 
the RV and RVOT is shown in table 2.2. 
 
Measurement 
Reference 
range 
Mildly dilated 
Moderately 
dilated 
Severely 
dilated 
Basal RV diameter (cm) 2.0-2.8 2.9-3.3 3.4-3.8 >3.8 
Mid-RV diameter (cm) 2.7-3.3 3.4-3.7 3.8-4.1 >4.1 
Base-apex length (cm) 7.1-7.9 8.0-8.5 8.6-9.1 >9.1 
RVOT 1 (cm) 2.5-2.9 3.0-3.2 3.3-3.5 >3.5 
RVOT2 (cm) 1.7-2.3 2.4-2.7 2.8-3.1 >3.1 
 
Table 2.2 Reference limits for RV and RVOT dimensions 
 
RV systolic function was assessed using a combination of 2D fractional 
area change, TAPSE and RV S’. RV fractional area change was 
calculated in the apical four chamber view (percentage change in RV area 
between diastole and systole). Normal was considered to be 32-60% with 
mildly abnormal classed as 25-31%, moderately abnormal 18-24% and 
severely abnormal <18%. TAPSE was measured by passing the M-mode 
cursor through the lateral annulus of the tricuspid valve in the apical four 
chamber view and recording the maximal longitudinal displacement of the 
annulus. In a normal RV, the tricuspid annulus will descend 1.5-2.0 cm. 
Measurements <1.5 cm were considered abnormal. Pulsed tissue Doppler 
was used to measure the longitudinal velocity of excursion in the apical 
four chamber view. Ensuring optimum image orientation, the pulsed 
Doppler sample volume was placed in the middle of the basal segment of 
the RV free wall. RV S’ was measured as the highest systolic velocity. S’ 
<10cm/s was considered abnormal. If all three of fractional area change, 
TAPSE and RV S’ were within normal limits, RV systolic function was 
considered normal. Degrees of abnormality were based on the fractional 
area change.  
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2.4 Statistical Methods 
 
2.41 Basic Principles 
Statistical analyses were performed using SPSS Version 20, statistical 
software (SPSS, Chicago, USA) and Stata/IC 12.0 software (StataCorp 
LP, College Station, TX, USA). A P-value<0.05 was considered 
statistically significant.  
 
Comparisons between continuous variables were made using the Mann-
Whitney U test, as the data did not satisfy the assumption of equal 
variances for the two-sample t-test. Categorical variables were compared 
using the Chi-square test, or Fisher’s exact test where cell counts were 
insufficient.  
 
Since relationships between the concentration of each biomarker and 
echocardiographic score were clearly non-linear, Spearman’s rank 
correlation coefficient (r) was used to measure statistical dependence 
between the two variables. 
 
2.42 ROC Analysis 
In order to assess the value of each biomarker as a diagnostic test for 
carcinoid heart disease, non-parametric ROC curves were constructed. 
The sensitivity (true-positive rate) of each biomarker was plotted against 1- 
the specificity (false positive rate) so as to determine the performance of 
the biomarker as its discrimination threshold was varied.  
 
2.43 Likelihood Ratios 
In addition to sensitivity and specificity, likelihood ratios (LR) were used to 
assess the diagnostic accuracy of different scores. These ratios use the 
sensitivity and specificity of the test to determine whether the test result 
usefully changes the probability that the disease is present.  They provide 
an indication of how more (LR+) or less (LR-) likely a patient with a given 
score is to have carcinoid heart disease, and can be used to calculate the 
‘post-test’ probability of having the disease (167). 
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2.44 Logistic Regression 
Multivariable logistic regression was used to assess whether any 
combination of biomarker assays was able to better discriminate between 
patients with and without carcinoid heart disease compared with any 
single assay. 
 
Multinomial logistic regression was used to assess the univariate 
association between a number of variables and (simultaneously) disease 
progression and death.  
 
2.45 Intra-observer Variability 
To assess intra-observer variability in the calculation of the carcinoid heart 
disease score, the author re-analysed ten percent of the echocardiograms 
performed as baseline scans, blinded to the initial score and diagnoses. 
The echocardiograms that were re-analysed were chosen at random. All 
re-analyses were performed at least 12 months after the echocardiograms 
had initially been performed. The intra-observer correlation coefficient for 
the carcinoid heart disease score was 0.99, indicating very good 
repeatability between measurements. Figure 2.1 illustrates the agreement 
between the original score and the recalculated score, with just 1 
measurement lying outside the 95% confidence interval.  
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Figure 2.1 Agreement plot (with 95% limits of agreement -1.19 to 1.30) 
 
2.46 Inter-observer Variability 
To ensure accurate reporting of the carcinoid heart disease score, and to 
validate echocardiographic data analysis, a randomly selected sub-group 
of echocardiographic studies were cross-checked by a different observer 
(JJ) for each chapter of the thesis. The independent observer was blinded 
to the author’s echocardiographic score. For the most complex scoring 
system, with a maximum score of 66, scores within two points were 
considered to be concordant. Where there was score discordance, a third 
independent observer (MB) analysed the echocardiographic study, blinded 
to the other scores. An average of the two most concordant scores was 
then used for these echocardiographic studies. 
  
  
Mean 
 
Difference 
Mean 
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Abstract 
 
Introduction Screening for carcinoid heart disease is an important, yet 
frequently neglected aspect of the management of patients with NETs. 
The aim of this study was to map current practice for the screening and 
management of carcinoid heart disease in specialist NET centres 
throughout the UK and Republic of Ireland. 
 
Methods Thirty-five NET centres were invited to complete an on-line 
questionnaire outlining the size of NET service, patient selection criteria 
for carcinoid heart disease screening, and the modality and frequency of 
screening.  
 
Results Twenty-eight centres responded (80%), representing over 5500 
patients. Eleven percent of centres screened all patients with any NET, 
14% screened only patients with midgut NETs, 32% screened all patients 
with liver metastases and/or carcinoid syndrome and 43% screened all 
patients with evidence of syndrome or raised urinary/serum/plasma 5-
hydroxyindoleacetic acid (5HIAA). Mode of screening included clinical 
examination, echocardiography and biomarker measurement: 89% of 
centres performed echocardiography, ranging from at initial presentation 
only (24%), periodically without clearly defined intervals (28%), annually 
(36%) or less than annually (12%); three centres used a scoring system to 
report their echocardiograms. 50% of centres utilised biomarkers for 
screening (chromogranins, plasma/urinary 5HIAA or most commonly 
NTproBNP) at varying time intervals.  
 
Conclusion There is considerable heterogeneity across the UK and 
Ireland in multiple aspects of screening and management of carcinoid 
heart disease.  
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3.1 Introduction 
 
Disparity in clinical interventions is well described in common diseases, 
such as atrial fibrillation (168) and deep vein thrombosis (168,169), and 
also in rare conditions such as Duchenne Muscular Dystrophy (170) and 
paediatric nephrotic syndrome (171). This variation in clinical practice can 
impact significantly on patient outcomes and the cost of health care (172). 
However, cohesive evidence based guidelines can reduce this disparity 
(173).  
 
Carcinoid heart disease occurs in 20-50% of patients with the carcinoid 
syndrome (25,153). The condition can be clinically silent, with no 
symptoms or signs of disease, even in patients with advanced pathology 
(50,54). There is considerable variation between international guidelines 
for the screening and management of carcinoid heart disease. 
Considering the heterogeneity in the literature, the aim of this study was to 
explore this further by mapping current UK and Republic of Ireland 
practice for carcinoid heart disease screening and management in 
specialist NET centres.  
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3.2 Methods 
 
Thirty-five specialist NET centres in the UK and Republic of Ireland were 
invited by email to complete an on-line questionnaire 
(www.surveymonkey.com) between August and September 2013. Centres 
were identified from the UKI NETs committee members and the NET 
Patient Foundation Website (http://www.netpatientfoundation.org/net-
expertise/net-centers/).  
 
The questionnaire consisted of ten questions relating to respondent 
demographics, population screened for carcinoid heart disease, mode and 
frequency of screening, access to cardiology expertise and criteria for 
consideration of valve surgery. The questions required a mixture of 
multiple choice and short answer responses (box 1). Questionnaires were 
completed by consultants working within the NET specialist service. All 
responses were kept confidential. 
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Box 1 – Questionnaire sent to all NET specialist centres 
1. Please state your name and institution 
2. How many years has your NET service been running? 
 0-5    6-10    11-15     16-20   >20 
3. Approximately how many NET patients do you manage at your 
institution? 
 <50      50-100    101-150    151-200      201-300    >300 
4. Who do you screen routinely for carcinoid heart disease?  
 All NET patients    Patients with syndrome 
 Patients with liver metastases  Do not screen routinely 
 Other 
5. How do you screen for carcinoid heart disease?  
 Clinical examination (if yes, how frequently?) 
 Regular echocardiography (if yes, how frequently?) 
 Biochemically (which biomarkers and how frequently?) 
 Patients are not screened routinely 
6. What information do you receive about the echocardiogram? 
 Standard echo report   Quantitative assessment using score  
7. Do you have a cardiologist on your MDT or a cardiologist with an 
interest in carcinoid heart disease to refer patients to?  
 Cardiologist on MDT   No cardiologist on MDT 
 Refer to cardiologist with interest in carcinoid heart disease 
 Refer to local general cardiology service 
8. Which patients do you refer to a cardiologist? 
 All patients with carcinoid heart disease  Other 
9. How frequently do your patients with carcinoid heart disease have an 
echocardiogram?  
 < Annually  Annually  Every 6 months  >Every 6 months 
10. What are your criteria for consideration of valve surgery? 
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3.3 Results 
 
3.31 Centre Demographics 
 
Twenty-eight centres (80%) completed the survey, representing a total 
caseload of over 5500 patients. The experience of each centre varied from 
less than five years to more than 20 years, reflecting more than 300 centre 
years of clinical experience with NETs. The NET patient caseload of each 
centre ranged from less than 50 patients to greater than 300, with 50% of 
centres managing in excess of 200 patients (figure 3.1). 
 
 
Figure 3.1 Relative size of each centre according to the total number of 
NET patients managed per centre 
 
3.32 Carcinoid Heart Disease Screening 
 
Screening for carcinoid heart disease occurred in all responding centres 
although the clinical characteristics of the population screened differed 
significantly between centres. Twelve centres screened only NET patients 
with carcinoid syndrome, nine centres screened patients with radiological 
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evidence of liver metastases or symptoms of carcinoid syndrome, four 
centres screened all patients with midgut NETs irrespective of the 
presence/absence of carcinoid syndrome/liver metastases and three 
centres screened all NET patients (figure 3.2). 
 
 
 
Figure 3.2 Clinical criteria for carcinoid heart disease screening 
 
The method employed to screen for carcinoid heart disease also varied 
enormously between centres. Sixty-eight percent (n=19) of centres used 
clinical examination as part of their screening process for carcinoid heart 
disease. Eighty-nine percent (n=25) of centres performed transthoracic 
echocardiography to screen patients for carcinoid heart disease with wide 
variation in the frequency of scans; 21% at baseline only, 32% annually, 
25% on an ad hoc basis and 11% less than annually. All centres received 
a standard clinical echocardiogram report with the exception of three 
centres which used an echocardiographic scoring system to quantify 
carcinoid heart disease.  
 
The use of biomarkers for the screening of carcinoid heart disease varied 
between centres, with one centre using it as the sole method of screening, 
All	NET	pa)ents	
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or	carcinoid	
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and others using it as an adjunct to clinical examination and/or 
echocardiography. In the 50% (n=14) of centres that routinely measured 
biomarkers, 50% (n=7) measured NTproBNP, 14% (n=2) measured 
5HIAA, 7% (n=1) measured chromogranins and 21% (n=3) measured a 
combination of the above. The frequency of biomarker measurement 
varied from bi-annually to once every two years. See table 3.1 for more 
details. 
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Centre Clinical 
examination 
Echocardiography Biomarkers Cardio
logist 
on 
MDT 
1 Ad hoc Annually NTproBNP annually ✗ 
2 6 monthly Annually  ✗ 
3 Annually Baseline then depending 
on symptoms 
 ✓ 
4 6 monthly Baseline then depending 
on symptoms 
Chromogranin ✗ 
5 3 monthly Dependent on clinical signs  ✗ 
6 3 monthly As indicated by clinical 
findings 
5HIAA, 
chromogranins 
✗ 
7 At each visit Less than annually 5HIAA ✓ 
8   NTproBNP every 2 
years 
✗ 
9  Annually NTproBNP 6 monthly ✓ 
10  Every 2-3 years  ✓ 
11  Annually  ✗ 
12 Annually Annually  
 
Biomarker not stated 
but measured 
annually 
✓ 
13 3 monthly If clinical suspicion   ✗ 
14 6 monthly   ✓ 
15 6 monthly  NTproBNP 6 monthly  ✓ 
16  Every 2-3 years  ✗ 
17 At each visit Baseline then if 
deterioration in carcinoid 
syndrome 
 ✓ 
18  Baseline  ✗ 
19 Annually Baseline NTproBNP at 
baseline 
✗ 
20 Baseline Those with elevated 
markers or symptoms 
5HIAA & NTproBNP 
(no frequency stated) 
✓ 
21 6 monthly Annually  ✓ 
22 3-12 monthly Practice and intervals vary  ✓ 
23 6 monthly Dependent on 5HIAA & 
clinical findings 
5HIAA 6-12 monthly  ✓ 
24 6 monthly Every 2 years Chromogranin & 
NTproBNP (no 
frequency stated) 
✓ 
25 Annually Annually NTproBNP 6 monthly ✓ 
26 6 monthly Annually NTproBNP 6 monthly ✗ 
27 6 monthly Annually  ✗ 
28  Baseline then depending 
on symptoms 
 ✗ 
 
Table 3.1 Method of cardiac screening and cardiology involvement across 
each NET centre 
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3.33 Cardiology Input and Referral 
 
A cardiology service with expertise in carcinoid heart disease was not 
available at all centres, with 50% (n=14) of centres lacking cardiology input 
to their MDT and 32% (n=9) of centres referring patients to their local 
general cardiology service. Eighty-six percent (n=24) of centres referred all 
patients with evidence of carcinoid heart disease to a cardiologist, with the 
remainder referring only those who were symptomatic, had moderate to 
severe valvular dysfunction, RV failure or cardiac metastases. Patients 
with established carcinoid heart disease were scanned at varying 
frequencies ranging from less than annually (35%), annually (48%), every 
6 months (13%) and more frequently than every 6 months (4%).  
 
Criteria for referral for valve surgery varied widely with some centres never 
referring patients (expressing the view that “surgery is not helpful in these 
patients”) and others referring all patients with carcinoid heart disease with 
a prognosis of greater than one year. There was a general feeling 
amongst respondents that decisions regarding valve surgery are difficult, 
and must be made in a multi-disciplinary setting. 
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3.4 Discussion 
 
This study demonstrates that there is wide variation in clinical practice with 
respect to screening methods for carcinoid heart disease across the UK 
and Republic of Ireland. There are variations in the population screened, 
in the frequency and mode of screening and in access to local cardiology 
expertise.  
 
Despite the uncertainty regarding the optimum management and timing of 
valvular surgery for patients with carcinoid heart disease, screening for 
cardiac involvement is imperative in order to identify patients who may be 
asymptomatic before they develop irreversible RV dysfunction. The clinical 
presentation of carcinoid heart disease is variable, with some patients 
presenting with fulminant heart failure, whilst others will be virtually 
asymptomatic. Early identification of patients enables monitoring for 
symptoms of right-sided heart failure or for echocardiographic evidence of 
RV dysfunction, and potentially an opportunity to slow the progression of 
carcinoid heart disease through the proactive reduction of serotonin levels 
by SSA therapy (54).  
 
Which clinical group to screen for carcinoid heart disease remains a 
contentious issue, with inconsistencies between the various guidelines 
adding to the confusion  (13,126). This is reflected in the variation of the 
populations screened in this study. As elevated concentrations of 
serotonin play a key role in the pathogenesis of carcinoid heart disease, 
the author advocates that all patients with raised plasma/serum/urine 
5HIAA concentrations are at risk of cardiac involvement and warrant 
inclusion in a carcinoid cardiac surveillance programme. The risk of 
developing carcinoid heart disease is difficult to quantify as it varies in the 
literature, but a recent prospective study estimated the risk to be around 
20% in patients with carcinoid syndrome (54). 
 
Clinical examination is an unreliable method of identifying patients with 
carcinoid heart disease (54) and those centres that rely on this method for 
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screening are potentially missing patients with cardiac involvement. 
Echocardiography is the gold standard for detection of carcinoid heart 
disease (81) but is more expensive than biomarker measurement. 
Consensus guidelines recommend the use of serum NTproBNP 
measurement for carcinoid heart disease screening (13) but only 32% of 
centres measure this routinely.  
 
The rate at which patients with carcinoid syndrome develop carcinoid 
heart disease is thought to be between 17 and 35% over two to three 
years (4,56,122). Carcinoid heart disease development is more common 
in patients with frequent daily episodes of flushing (4). Despite 
international agreement that screening for carcinoid heart disease is an 
important aspect of NET patient care, the optimum frequency of screening 
remains uncertain. The screening frequency in this study varied widely 
from a one-off event at presentation, to regular screening every three 
months. 
 
Due to the relatively rare nature of carcinoid heart disease, it is 
recommended that all patients with evidence of carcinoid heart disease 
are considered for referral to a cardiologist with appropriate expertise or 
experience in this field (13). Only half of the centres surveyed had a 
cardiologist on their MDT and a third referred patients to the general 
cardiology service, who may have little or no experience in the 
management of carcinoid heart disease. Greater collaboration between 
specialist regional centres and centralisation of expertise would enable all 
NET services to access experienced specialist cardiology services. This 
study demonstrated that there is wide variation in the frequency of 
echocardiography in patients with documented carcinoid heart disease. As 
the presence of moderate to severe RV dilatation increases perioperative 
mortality (120), it has been suggested that early surgical intervention in 
patients with mildly symptomatic carcinoid heart disease is preferable  
(141). Therefore in order to identify patients before RV dilatation and 
failure ensues, annual echocardiography for patients with cardiac 
involvement is recommended  (126).  
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Indications for valve surgery varied between centres with some referring 
all patients with carcinoid heart disease, and others referring none. 
ENETS guidelines recommend consideration of bioprosthetic valve 
replacement for patients in whom control of tumour growth and hormonal 
symptoms has been achieved. Valvular surgery prior to major liver surgery 
or liver embolisation is also recommended  (126).  
 
A limitation of this study is that only 80% of centres responded to the 
survey, and not all patients with NETs are managed in specialist centres.  
Therefore, it is not a reflection of 100% of practice in the UK and Ireland. It 
is possible that there is a selection bias in the method by which centres 
were identified. Use of the National Cancer Registry may have allowed a 
more comprehensive assessment of the treatment of NET patients within 
the UK and Republic of Ireland. One further limitation is that it is possible 
that different clinicians in the same hospital might follow different 
protocols, or even the same clinician may use different criteria from one 
patient to the next. This was not reflected in the information obtained from 
the centres but cannot be completely ruled out. Finally, these data are not 
validated, we have only the information given to us by each centre but as 
a review of the case notes of every individual with a NET was not possible, 
this was the best way of discerning clinical practice.  
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3.5 Conclusion 
 
This study has demonstrated that compliance with current guidelines for 
carcinoid heart disease is relatively poor. There are several possible 
reasons for this, including lack of clinician awareness, lack of clinical 
resources and conflicting guidelines. Standardisation of nationwide 
practice in the management of carcinoid heart disease in accordance with 
a consensus guideline would facilitate a UK registry of patients with 
carcinoid heart disease to better understand the natural history and 
prognosis of this condition and potentially improve patient outcomes for 
the disease across the UK and Ireland. 
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Abstract 
 
Introduction  
Metastatic NETS secrete serotonin and other vasoactive substances that 
are responsible for carcinoid syndrome and carcinoid heart disease. The 
aim of this study was to evaluate the discriminatory utility of diagnostic 
biomarkers in determining the presence and severity of carcinoid heart 
disease in patients with metastatic NETs. 
 
Methods  
A cross-sectional study of patients with NETs with documented liver 
metastases and/or carcinoid syndrome between April 2009-October 2012 
in four tertiary referral centres was undertaken. Serum was analysed for 
CgA, Cg B and NTproBNP. Plasma was analysed for Nk A and 5HIAA. 
Echocardiography was used to determine the presence and severity of 
carcinoid heart disease. Non-parametric ROC were constructed for each 
biomarker, and the area under the curve (AUC) determined. The severity 
of cardiac involvement was correlated with the concentration of each 
biomarker.  
 
Results  
A total of 187 patients were identified of whom 37 (20%) had carcinoid 
heart disease. Significantly higher median values of all biomarkers were 
found in the patients with cardiac involvement. NTproBNP and plasma 
5HIAA had the highest AUCs for the prediction of carcinoid heart disease: 
NTproBNP 0.82 (95% confidence interval 0.74-0.90, p<0.0001) and 5HIAA 
0.85 (95% confidence interval 0.78-0.92, p<0.0001). NTproBNP was 
moderately correlated (r=0.48, p<0.001) whereas plasma 5HIAA was only 
weakly correlated (r=0.34, p<0.001) with the echocardiographic severity 
score.  
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Conclusion  
NTproBNP and plasma 5HIAA are both sensitive and specific biomarkers 
for the presence of carcinoid heart disease whereas only NTproBNP 
moderately correlates with disease severity. 
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4.1 Introduction 
 
Metastatic mid-gut NETs secrete serotonin and a variety of other 
vasoactive substances that are responsible not only for the characteristic 
carcinoid syndrome, but also for the significant long-term complication of 
carcinoid heart disease.  
   
Echocardiography is a pivotal tool for the assessment of carcinoid heart 
disease. Whilst echocardiography is the gold-standard investigation, the 
use of biomarkers to identify those patients most at risk is cheaper, less 
time-consuming and a more practical option. The identification of a 
sensitive and specific biochemical marker that can predict the presence 
and severity of carcinoid heart disease may direct more rational use of 
echocardiographic screening. 
   
A variety of biomarkers for carcinoid heart disease have been identified in 
previous studies (see chapter one, section 1.34). The most useful to date 
has been NTproBNP, which has both diagnostic and prognostic 
significance for cardiac involvement (52,55). No studies of patients with 
metastatic NETS that compare the discriminatory ability of a panel of 
biomarkers in the assessment of the presence and severity of carcinoid 
heart disease have been identified in the literature. 
 
The aim of this study was to determine which biomarker was best 
associated with the presence and severity of carcinoid heart disease in 
patients with metastatic NETs.  
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4.2 Methods 
 
For an in-depth explanation of recruitment, echocardiographic, 
biochemical and statistical methods, please refer to chapter two.  
 
Inter-observer Variability 
Inter-observer agreement was ascertained as per the methods in chapter 
2. One hundred and eight echocardiographic studies (57%) were 
validated. In 98 studies the assigned scores were concordant, in ten there 
was a discrepancy of >2 points, (mean difference 0.269).  
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4.3 Results 
 
4.31 Patient Demographics 
 
Two hundred and eighteen patients were invited to participate. Figure 4.1 
details the reasons for exclusion of 31 patients. A total of 187 patients 
were included. The baseline characteristics of the patients are shown in 
Table 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Consort flow diagram 
 
One hundred and sixty-six patients had a histologically confirmed NET. Of 
the 121 patients with a Ki67 proliferative index reported: 69 patients had a 
grade one tumour (Ki67 <2%), 50 patients had grade two tumours (Ki67 2-
20%) and two patients’ tumours were grade three (Ki67 >20%). Thirty-one 
patients were newly diagnosed (<three months since presentation) while 
156 had an established diagnosis with a median duration of 56 months 
Assessed for eligibility (n=218) 
Excluded at start of study: 
• Inability to provide informed 
consent (n=1) 
• Refused consent (n=1) 
• Prosthetic valves (n=3) 
 
Excluded following echocardiogram: 
Inadequate visualisation of all 4 valves 
(n=26) 
 
Total cohort  
(n=187) 
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(interquartile range 35-93 months).  
 
There were no significant differences with respect to age, gender, or 
primary tumour site between the groups with and without carcinoid heart 
disease. Furthermore there was no difference in duration of disease 
between the two groups (median duration 47 v 29 months, P=0.102). 
There were no significant differences in the proportions of patients with a 
history of chronic obstructive pulmonary disease or ischaemic heart 
disease between the groups.  
 
The proportions of patients with liver metastases and symptoms of heart 
failure were higher in those with carcinoid heart disease than in those 
without. Those patients who had undergone primary tumour resection had 
a significantly lower prevalence of carcinoid heart disease than those 
without primary tumour resection, although this was not the case for 
patients who had or had not undergone hepatic resection.  
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Variable All patients (n=187) 
No carcinoid 
heart 
disease 
(n=150) 
Carcinoid 
heart 
disease 
(n=37) 
Demographics 
Age (years)  67 ± 10 66 ± 10 68 ± 12 
Male sex 101 (54%) 84 (56%) 17 (44%) 
Body mass index (kg/m2)  25.9 ± 5.0 26.6 ± 4.5 * 22.1 ± 6.0 * 
Clinical Characteristics 
Histologically confirmed 
diagnosis 
166 (89%) 136 (90%) 30 (83%) 
Duration of disease (months) ¸  42 (26-74) 47 (28-79) 29 (9-63) 
New NET diagnosis at time of 
echocardiogram 
32 (17%) 23 (15%) 9 (24%) 
Proton pump inhibitor therapy 54 (29%) 46 (30%) 8 (22%) 
Liver metastases 156 (83%) 119 (79%) * 37 (97%) * 
Carcinoid syndrome 120 (64%) 95 (63%) 25 (68%) 
Site of Primary Tumour 
Small bowel 132 (71%) 108 (72%) 24 (67%) 
Large bowel 12 (6%) 11 (7%) 1 (3%) 
Lung 5 (3%) 5 (3%) 0 
Other 7 (4%) 4 (3%) 3 (8%) 
Unknown  31 (16%) 23 (15%) 8 (22%) 
NYHA Class/Medical History 
I 133 (71%) 117 (78%) * 16 (44%) * 
II 49 (26%) 33 (22%) 16 (44%) 
III 4 (2%) 1 (0.5%) 3 (8%) 
IV 1 (1%) 0 1 (3%) 
History of COPD 9 (5%) 7 (5%) 2 (5%) 
History of IHD 13 (7%) 11 (7%) 2 (5%) 
Therapeutic Intervention 
SSA therapy 
89 (48%) 68 (45%) 21 (58%) 
Primary tumour resection 
118 (63%) 101 (67%) * 17 (47%) * 
Hepatic resection 
19 (10%) 18 (12%) 1 (3%) 
 Mean ± standard deviation, ¸ Median and interquartile range, * P<0.05, COPD Chronic 
obstructive pulmonary disease, IHD Ischaemic heart disease 
 
Table 4.1 Baseline characteristics of patients  
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4.32 Echocardiography Results 
 
Thirty-seven patients (20%) had echocardiographic evidence of carcinoid 
heart disease. The median echocardiographic score in those with cardiac 
involvement was 12 (interquartile range (IR) 8-21), compared to a median 
of two (IR 1-3) in those without cardiac involvement. There were 24 cases 
of single valve involvement (tricuspid in 23 cases, pulmonary in one), 12 
cases of dual valve pathology, and one patient with three valves involved. 
The right heart was dilated in 34 cases and RV function was affected in 
ten cases. Eight patients (4%) had evidence of left sided carcinoid heart 
disease. The echocardiographic score was weakly correlated with NYHA 
class, i.e. patient symptoms (Spearman r=0.22; P=0.002).  
 
4.33 Predictive Value of Biomarkers for The Diagnosis of Carcinoid 
Heart Disease 
 
Significantly higher median values of all biomarkers were found in the 
patients with carcinoid heart disease compared to those without (figure 
4.2). NTproBNP 474 vs. 79 ng/L, 5HIAA 353 vs. 57 ng/ml, CgA 16 vs. 7 
ng/ml, CgB 13 vs. 8 ng/ml and NkA 27 vs. 16 ng/L. Plasma 5HIAA and 
NTproBNP had the greatest AUCs (0.85 plasma 5HIAA and 0.82 NT-
proBNP, figure 4.3). The AUCs for CgA, CgB and NkA were 0.69 (0.57-
0.80), 0.77 (0.67-0.88) and 0.72 (0.62-0.82) respectively. 
 
The effect of age, sex and creatinine on NTproBNP was investigated using 
a multivariable prediction model. NTproBNP remained statistically 
significant whereas age, gender and creatinine did not (P=0.599, 0.521 
and 0.749 respectively). A stepwise model selection method (minimising 
Akaike’s Information Criterion (AIC)) demonstrated that age, gender and 
creatinine do not offer any additional information to discriminate between 
patients with and without carcinoid heart disease (univariate P-values of 
0.277, 0.300 and 0.822 respectively). 
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Figure 4.2 Box plots demonstrating spread of results for all five 
biomarkers 
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Figure 4.3 Receiver operator characteristic curves for NTproBNP and 
plasma 5HIAA 
 
The cut-off points for NTproBNP and plasma 5HIAA with their respective 
sensitivities and specificities in this patient cohort are illustrated in table 
4.2. The improvement in discriminatory power by inclusion of additional 
assays into a final logistic regression model was negligible (less than 5-
point change in AIC; direct comparison of full model with plasma 5HIAA 
yielded P=0.682). For every 50 ng/l increase in NTproBNP concentration, 
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the odds of carcinoid heart disease increased by 11% (95% confidence 
interval 5-17%, P<0.0005) and for every 50 ng/ml increase in plasma 
5HIAA the odds of carcinoid heart disease increased by 26% (95 
confidence interval 14-39%, P<0.0005). 
 
NTproBNP 
cut point 
(ng/L) 
Sens. Spec. Correctly classified 
Proportion 
above  
cut-point 
LR + LR - 
100 88 54 55% 55% 1.9 0.2 
200 74 73 73% 37% 2.8 0.3 
300 67 82 79% 28% 3.6 0.4 
400 61 87 81% 23% 4.6 0.4 
500 50 93 84% 16% 6.8 0.5 
600 42 95 84% 13% 8.1 0.6 
5HIAA cut 
point 
(ng/ml) 
      
50 93 45 54% 96% 1.7 0.1 
100 80 68 71% 82% 2.5 0.3 
150 73 80 79% 74% 3.7 0.3 
200 70 85 83% 68% 4.8 0.4 
250 67 87 83% 63% 5.1 0.4 
300 57 88 83% 58% 4.9 0.5 
350 50 92 84% 54% 5.9 0.5 
Sens Sensitivity, Spec Specificity, LR + Positive likelihood ratio, LR - Negative likelihood 
ratio 
 
Table 4.2 Diagnostic accuracy of NTproBNP & plasma 5HIAA 
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4.34 Correlation Between Biomarkers and Echocardiographic 
Severity Score  
 
There were significant correlations between the echocardiographic score 
and concentrations of all biomarkers except CgA. The score correlated 
most significantly with NTproBNP (Spearman r=0.48; P<0.0001) while for 
the other biomarkers the correlation coefficients were low: plasma 5HIAA 
(Spearman r=0.34; P<0.0001), CgA 0.09 (P=0.25), CgB 0.29 (P<0.0001) 
and NkA 0.19 (P=0.03), figure 4.4. 
 
 
 
 
Figure 4.4 Scatter diagram demonstrating correlations of NTproBNP and 
plasma 5HIAA with the echocardiographic score 
 
 
 
 
 
 
 
  
 92 
4.4 Discussion 
 
This is the first large prospective clinical study of patients with metastatic 
NETs to compare the discriminatory ability of a panel of biomarkers in the 
assessment of the presence and severity of carcinoid heart disease. The 
data demonstrate that the median concentrations of all five biomarkers are 
significantly higher in patients with carcinoid heart disease, however 
NTproBNP and plasma 5HIAA have the greatest discriminatory value in 
the diagnosis of carcinoid heart disease, with NTproBNP most closely 
correlating with its severity. Thus in this panel of biomarkers for use in 
patients with metastatic NETs, NTproBNP concentration is the most useful 
biochemical assay for clinicians regarding the presence and severity of 
cardiac involvement. This finding is consistent with the most recent 
ENETS and NANETs consensus guidelines advocating the use of 
natriuretic peptides where available  (126,127).  
 
The optimum cut-off point for NTproBNP is determined by the relative 
importance of the sensitivity and specificity of the test. In this 
circumstance, sensitivity assumes greater importance than specificity, as it 
is preferable to perform echocardiography on too many patients, rather 
than miss a diagnosis of carcinoid heart disease. Unlike the results of 
Korse et al. (55), no incremental benefit in combining NTproBNP with CgA 
was found, although there was minor incremental benefit in combining 
NTproBNP and plasma 5HIAA in terms of increasing the diagnostic 
accuracy of the test. A single variable model was considered to be 
favourable due to its enhanced ease of use in clinical practice. In this 
series, the cut-off point for NTproBNP of 260 pg/ml suggested by 
Bhattacharya (53), would have a sensitivity of 69% and a specificity of 
80%, meaning that 11 patients with carcinoid heart disease would not 
have been detected.  
  
NTproBNP is released from cardiac myocytes with myocyte stretch being 
the main stimulus for its synthesis and secretion (161). Elevated levels 
reflect increased wall tension and pressure making its measurement of 
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value in carcinoid heart disease. The finding of the correlation between the 
degree of elevation of plasma 5HIAA and the development of carcinoid 
heart disease gives mechanistic insight into the likely contribution of 
serotonin to the pathogenesis of cardiac involvement. The use of SSAs 
that are known to reduce circulating levels of serotonin may be expected 
to be protective against the development of carcinoid heart disease but we 
were unable to confirm this hypothesis. This negative association likely 
reflects a treatment bias, in that patients with a greater tumour burden are 
more likely to require treatment with SSAs. Furthermore 83% of this cohort 
had liver metastases and 64% had carcinoid syndrome but only 48% 
received SSAs, which may have influenced the findings. Ideally, 
prospective human studies are needed to determine whether SSAs can 
prevent or decrease the severity of carcinoid heart disease, although the 
anti-proliferative effect of SSAs may result in an increasingly higher 
proportion of patients with metastatic NETs receiving them.  
 
In this study there was a poor correlation between CgA and the severity of 
carcinoid heart disease which may be because CgA is falsely elevated by 
proton pump inhibitor (PPI) therapy in healthy individuals (174), and those 
with NETs (175). Thirty percent of patients who did not have carcinoid 
heart disease were taking PPI therapy, which undoubtedly will have 
influenced the CgA results. CgB, however, is not affected by renal function 
or PPI therapy (72). This may explain why our data demonstrate that CgB 
is more sensitive and specific than CgA for carcinoid heart disease. NkA is 
a specific marker for tumours of the mid-gut (73) and the inclusion of a 
minority of patients with NETs not of mid-gut origin may have affected the 
NkA results for this patient cohort. 
  
The distribution of NYHA categories in patients with carcinoid heart 
disease (88% of patients in categories one and two) demonstrates that the 
disease is often clinically silent, with no discernable attributable symptoms. 
This is reflected in the weak correlation of the echocardiographic score 
with NYHA class.  
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While the strength of this study is the large population of NET patients, 
carefully characterised prospectively from a multi-modality perspective 
with a comparison of multiple biomarkers, there are some limitations. Most 
significantly, the exclusion of patients in whom it was not possible to 
visualise all four cardiac valves may have led to an underestimate in the 
prevalence of carcinoid heart disease.  
 
The findings suggest that NTproBNP or plasma 5HIAA could direct the 
use of transthoracic echocardiography in the assessment of patients with 
metastatic NETs. As a result, the author proposes that all such patients 
undergo a baseline echocardiogram at diagnosis or initial assessment, 
and if there is no evidence of cardiac involvement, echocardiography is 
only repeated in the event of an increase in NTproBNP. Such an approach 
would necessitate a proportion of patients without carcinoid heart disease 
being screened unnecessarily but would successfully identify the vast 
majority of patients with the disease. The author recognises that 
NTproBNP is not highly specific and therefore unsuitable for monitoring 
patients with an elevated NTproBNP attributable to a different pathology. 
In this scenario, it is necessary to resort to annual echocardiography.  
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4.5 Conclusion 
 
In conclusion, this study demonstrates that NTproBNP and plasma 5HIAA 
are equally useful in determining the diagnosis of carcinoid heart disease. 
NTproBNP correlates better with severity of disease and may be superior 
to determine progression but both biomarkers could be used as part of the 
routine surveillance protocol in patients with metastatic NETs. 
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Abstract 
 
Introduction Carcinoid heart disease is an important complication of 
metastatic neuroendocrine disease, requiring regular monitoring to enable 
intervention prior to right heart failure. The aim of this study was to identify 
the most appropriate echocardiographic scoring system for the 
quantitative assessment of carcinoid heart disease. 
 
Methods In this prospective study of patients with NETs with liver 
metastases and/or carcinoid syndrome, patients underwent transthoracic 
echocardiography and blood sampling for serum NTproBNP and plasma 
5HIAA. Each patient was assessed according to six echocardiographic 
scoring systems. The individual scoring system’s feasibility, observer 
variability, sensitivity, specificity and correlation with the concentration of 
biomarkers were determined. 
 
Results One hundred patients were included, 21% had echocardiographic 
evidence of carcinoid heart disease. All scores discriminated highly 
between those with/without carcinoid heart disease, with no single score 
performing significantly better than another. Severity of disease, 
determined using all of the scoring systems, correlated with the 
concentration of both biomarkers. However the strongest correlations were 
seen between the Bhattacharyya score and serum NTproBNP.  
 
Conclusion All scoring systems were comparable in terms of sensitivity 
and specificity for the detection of carcinoid heart disease. There was 
variation in the feasibility of the scoring systems due to the varying 
complexity of the score components. All scores correlated with NTproBNP 
and plasma 5HIAA. The Westberg score appeared to be the most optimal 
scoring system for use in the screening of carcinoid heart disease 
whereas the more complex scoring systems were more suited to the 
patient with established disease who may require surgical intervention. 
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5.1 Introduction 
 
Carcinoid heart disease is associated with considerable morbidity and 
mortality and is characterised by thickening of the right-sided valves, 
reduced excursion of the valve leaflets and consequent regurgitation 
and/or stenosis which can lead to right heart failure (25,42).  
  
Early diagnosis and regular monitoring for progression of carcinoid heart 
disease is important as it can impact drastically on long-term survival, and 
timely valve replacement is imperative for a successful outcome (57,120). 
Transthoracic echocardiography is the gold standard investigation for the 
diagnosis and surveillance of carcinoid heart disease (9,81) but there is no 
consensus over which screening method most accurately quantifies 
disease.  
 
Several echocardiographic scoring systems have been developed for the 
assessment of carcinoid heart disease, but have been used with limited 
evaluation of their validity and utility. Consequently there is uncertainty 
surrounding the clinical relevance of these scoring systems.  
   
A prospective study was conducted to apply and compare different 
echocardiographic scoring systems in a large population of patients with 
metastatic NETs attending specialist neuroendocrine clinics in ENETS 
Centres Of Excellence. The aims of the study were to identify the different 
uses of the scoring systems and to determine the most appropriate 
echocardiographic scoring system for the quantitative assessment of 
carcinoid heart disease.  
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5.2 Methods 
 
For an in-depth explanation of recruitment, echocardiographic, 
biochemical and statistical methods, please refer to chapter two.  
 
5.21 Literature Review 
PubMed and Medline databases were searched with the terms carcinoid 
heart disease, echocardiography, scoring system, score and grade, with 
identification of 17 papers. Ten papers were excluded as they related to 
different cardiac imaging modalities or did not use an echocardiographic 
scoring system. Several papers utilised the same scoring systems; there 
was ultimate identification of five different scoring systems  
(49,50,53,120,123), see chapter one for more details. 
 
5.22 Scoring Systems 
The five scoring systems are described in detail in chapter one. Table 1.4 
illustrates the different echocardiographic scoring systems for carcinoid 
heart disease, which range considerably in their complexity. A score for 
each scoring system was calculated, wherever possible, for each patient.  
  
Valve regurgitation and stenosis were quantified according to the same 
standards or guidelines used in the original papers citing the scores. An 
additional score (Dobson), incorporating what the author considered to be 
the most clinically relevant aspects of the other scores, was also 
calculated. This comprised a 33-point score, with three points (0 points 
equating to normality and 3 points equalling severe abnormality) 
attributable to each of the following variables: tricuspid and pulmonary 
valve thickening, leaflet mobility, regurgitation, and stenosis (each valve 
scored separately) and right atrial size, RV size and RV function.  
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5.23 Inter-observer Variability 
 
Inter-observer agreement was ascertained as per the methods in chapter 
two. To evaluate inter-observer agreement a randomly selected 
subsample of ten echocardiographic scans were crosschecked by a 
different observer blinded to the initial echocardiographic scores, who 
calculated all six scores for each scan. There was concordance between 
the two reviewers’ interpretation of all of the different scoring systems for 
all of the scans: the mean difference between the different scoring 
systems was 1.1 (Bhattacharyya), 0.4 (Denney), 0.6 (Dobson), 0.8 
(Mansencal), 0.9 (Moller) and 0.5 (Westberg). 
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5.3 Results 
 
5.31 Patient Demographics 
 
One hundred and three patients were assessed for their eligibility for the 
study with three patients meeting the criteria for exclusion (one patient had 
an aortic valve prosthesis and two patients had poor echocardiographic 
images precluding comprehensive assessment of all four cardiac valves). 
Of the 100 patients included, 21 had echocardiographic evidence of 
carcinoid heart disease. 
 
There were no significant differences between those with and without 
carcinoid heart disease in terms of age, gender, disease duration, primary 
tumour site, presence of liver metastases or carcinoid syndrome or 
therapeutic intervention received. The demographics, clinical 
characteristics, biochemistry and therapeutic interventions for the cohort 
are shown in table 5.1. 
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Variable All 
patients  
(n=100) 
No 
carcinoid 
heart 
disease 
(n=79) 
Carcinoid 
heart 
disease 
(n=21) 
P value 
Demographics 
 
Age (years) ¸ 
 
Male sex  
 
Body mass index (kg/m2) ¸ 
 
 
 
66.3 ± 10.6 
 
55 (55%) 
 
26.7 ± 4.9 
 
 
65.6 ± 10.1 
 
46 (58%) 
 
27.5 ± 4.8 
 
 
68.7 ± 12.2 
 
9 (43%) 
 
23.5 ± 4.0 
 
 
0.24 
 
0.21 
 
0.002 * 
Clinical Characteristics 
 
Duration of disease (months)  
 
Time from NET diagnosis to 
echocardiogram (months)         
  
Site of primary tumour 
      Small bowel 
      Large bowel 
      Lung 
      Ovarian 
      Gastric 
      Unknown 
 
NYHA Class 
    I  
    II 
    III   
    IV 
 
Liver metastases  
 
Carcinoid syndrome  
 
 
40 (15-74) 
 
34 (9-69) 
 
 
 
73 
6 
2 
1 
1 
17 
 
 
63 
36 
1 
0 
 
90 
 
71 
 
 
41 (18-74) 
 
36 (11-69) 
 
 
 
57 (72%) 
5 (6%) 
2 (3%) 
0 
1 (1%) 
14 (18%) 
 
 
51 (65%) 
27 (34%) 
1 (1%) 
0 
 
70 (89%) 
 
56 (71%) 
 
 
30 (9-71) 
 
22 (6-66) 
 
 
 
16 (76%) 
1 (5%) 
0 
1 (5%) 
0 
3 (14%) 
 
 
12 (57%) 
9 (43%) 
0 
0 
 
20 (95%) 
 
15 (71%) 
 
 
0.62 
 
0.33 
 
 
 
0.78 
 
 
 
 
 
 
 
0.68 
 
 
 
 
0.37 
 
0.96 
Biochemistry 
 
NTproBNP ng/L  
 
 
5HIAA nmol/L  
 
 
 
109  
(46-307) 
 
415  
(140-1474) 
 
 
79 
(27-185) 
 
285 
(103-854) 
 
 
290 
(110-611) 
 
2288 
(999-3294) 
 
 
0.013 * 
 
 
0.004 * 
Management 
 
Somatostatin Analogue 
 
Primary tumour resection 
 
Hepatic resection 
 
 
51 
 
52 
 
10 
 
 
41 (52%) 
 
43 (54%) 
 
9 (11%) 
 
 
 
10 (48%) 
 
9 (43%) 
 
1 (5%) 
 
 
0.95 
 
0.35 
 
0.37 
NYHA New York Heart Association, ¸ Mean ± standard deviation,  Median (interquartile 
range), * P< 0.05 
 
Table 5.1 Characteristics of the patient population  
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5.32 Echocardiographic Characteristics of the Cohort 
 
All patients with carcinoid heart disease had moderate or severe tricuspid 
regurgitation, making it the most common valvular pathology observed. 
Two thirds of patients with carcinoid heart disease had pulmonary 
regurgitation. Tricuspid stenosis occurred in 43% of patients, and 
pulmonary stenosis was the least prevalent right-sided valvular lesion, 
occurring in 24% of cases. Forty-three percent of patients with carcinoid 
heart disease had a degree of RV dilatation. Fourteen patients had single 
valve pathology and seven had two or more valves involved. Determining 
the presence of left-sided valve disease is challenging, as it possible to 
have right-sided carcinoid heart disease, concomitant with degenerative 
left-sided valvular disease. Two patients had clear echocardiographic 
evidence of right and left-sided carcinoid heart disease, both of which had 
patent foramen ovale. The specific features of cardiac involvement in this 
cohort are illustrated in tables 5.2a, 5.2b and 5.3. 
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Morphology 
Variable – no (%) All (n=100) No CHD (n=79) CHD (n=21) 
Tricuspid leaflet thickening 
None 
Mildly thickened 
Moderately thickened 
Severely thickened 
 
60 
26 
8 
6 
 
60 (76%) 
19 (24%) 
0 
0 
 
0 
7 (33%) 
8 (38%) 
6 (29%) 
Tricuspid leaflet mobility 
Normal 
Mildly reduced 
Moderately reduced 
Severely reduced 
 
78 
12 
5 
4 
 
 
78 (99%) 
0 
0 
0 
 
 
0  
12 (57%) 
5 (24%) 
4 (19%) 
 Pulmonary leaflet thickening 
Unable to visualise 
None 
Mildly thickened 
Moderately thickened 
Severely thickened 
 
3 
73 
22 
1 
1 
 
2 
67 (87%) 
10 (13%) 
0 
0 
 
 
1 
6 (30%) 
12 (60%) 
1 (5%) 
1 (5%) 
 Pulmonary leaflet mobility 
Unable to visualise 
Normal 
Mildly reduced 
Moderately reduced 
Severely reduced 
 
3 
92 
3 
2 
1 
 
2 
77 (97%) 
0 
0 
0 
 
1 
15 (71%) 
3 (14%) 
2 (10%) 
1 (5%) 
RV dilatation 
None 
Mild 
Moderate 
Severe 
 
83 
10 
2 
5 
 
71 (90%) 
7 (9%) 
1 (1%) 
0 
 
12 (57%) 
3 (14%) 
1 (5%) 
5 (24%) 
 
Table 5.2a Echocardiographic characteristics of the right heart 
(morphology)  
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Function 
Variable – no (%) All (n=100) No CHD (n=79) CHD (n=21) 
Tricuspid stenosis  
None 
Mild 
Moderate 
Severe 
 
 
 
93 
5 
2 
0 
 
79 (100%) 
0 
0 
0 
 
12 (57%) 
7 (33%) 
2 (10%) 
0 
 Tricuspid regurgitation  
None 
Mild 
Moderate 
Severe   
  
 
26 
49 
15 
10 
 
26 (33%) 
49 (62%) 
4 (5%) 
0 
 
0 
0 
11 (52%) 
10 (48%) 
Pulmonary stenosis  
None 
Mild 
Moderate 
Severe 
 
95 
4 
1 
0 
 
79 (100%) 
0 
0 
0 
 
16 (76%) 
4 (19%) 
1 (5%) 
0 
Pulmonary regurgitation  
None 
Mild 
Moderate 
Severe  
 
59 
37 
2 
2 
 
52 (66%) 
27 (34%) 
0 
0 
 
7 (34%) 
10 (48%) 
2 (9%) 
2 (9%) 
 
Table 5.2b Echocardiographic characteristics of the right heart (function)
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Morphology Function 
Variable – no (%) All 
(n=100) 
No carcinoid 
heart disease 
(n=79) 
Carcinoid 
heart 
disease 
(n=21) 
Variable – no (%) All  
(n=100) 
No carcinoid 
heart disease 
(n=79) 
Carcinoid 
heart 
disease 
(n=21) 
Mitral leaflet thickening 
None 
Mildly thickened 
Moderately thickened 
Severely thickened 
 
50 
44 
6 
0 
 
44 (56%) 
31 (39%) 
4 (5%) 
0 
 
6 (29%) 
13 (62%) 
2 (9%) 
0 
Mitral stenosis  
None 
Mild 
Moderate 
Severe 
 
 
 
100 
0 
0 
0 
 
79 (100%) 
0 
0 
0 
 
21 (100%) 
0 
0 
0 
Mitral leaflet mobility 
Normal 
Mildly reduced 
Moderately reduced 
Severely reduced 
 
91 
8 
1 
0 
 
75 (95%) 
4 (5%) 
0 
0 
 
16 (76%) 
4 (19%) 
1 (5%) 
0 
Mitral regurgitation  
None 
Mild 
Moderate 
Severe   
  
 
55 
42 
3 
0 
 
45 (57%) 
31 (39%) 
3 (4%) 
0 
 
10 (48%) 
11 (52%) 
0 
0 
Aortic leaflet thickening 
None 
Mildly thickened 
Moderately thickened 
Severely thickened 
 
63 
27 
10 
0 
 
55 (70%) 
19 (24%) 
5 (6%) 
0 
 
8 (38%) 
8 (38%) 
5 (24%) 
0 
Aortic stenosis  
None 
Mild 
Moderate 
Severe 
 
100 
0 
0 
0 
 
79 (100%) 
0 
0 
0 
 
21 (100%) 
0 
0 
0 
Aortic leaflet mobility 
Normal 
Mildly reduced 
Moderately reduced 
Severely reduced 
 
95 
5 
0 
0 
 
76 (96%) 
3 (4%) 
0 
0 
 
15 (71%) 
2 (10%) 
4 (19%) 
0 
 
Aortic regurgitation  
None 
Mild 
Moderate 
Severe  
 
71 
22 
7 
0 
 
61 (77%) 
15 (19%) 
3 (4%) 
0 
 
10 (48%) 
7 (33%) 
4 (19%) 
0 
 
 
 
Table 5.3 Echocardiographic characteristics of the left heart
 107 
5.33 Biomarkers 
 
The patients with carcinoid heart disease had significantly higher median 
values of both NTproBNP (290 v 79 ng/L, P=0.013) and plasma 5HIAA 
(2288 v 285 nmol/L, P=0.004) compared to patients without cardiac 
involvement.  All of the scoring systems correlated weakly or moderately 
with both biomarkers (table 5.4). The Bhattacharyya score was the most 
closely correlated with a single biomarker (NTproBNP; r=0.43, P<0.0001). 
 
5.34 Scoring systems 
 
A comparison of the scoring systems in our patient population is shown in 
table 5.4. The Westberg and Denney scores were the simplest to calculate 
and had the highest feasibilities (ability to calculate the score for a given 
patient). All scoring systems were comparable in terms of their ability to 
discriminate between those with and without carcinoid heart disease. The 
new scoring system did not have a significantly higher discriminatory 
ability for the detection of carcinoid heart disease. Figure 5.1 illustrates the 
distribution of scores for each scoring system for those with and without 
carcinoid heart disease. Table 5.5 illustrates the diagnostic accuracy of the 
six scoring systems with the sensitivity and specificity for the diagnosis of 
carcinoid heart disease at different scores presented.  
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 Bhattacharyya Denney Dobson Mansencal Moller Westberg 
Feasibility 97% 100% 94% 96% 86% 100% 
Score in carcinoid heart disease v 
no carcinoid heart disease ¸  
12 (10-21) 
v 
3 (2-5) 
8 (8-10) 
v 
4 (4-5) 
8.5 (7-18) 
v 
2 (1-2) 
8 (6-14) 
v 
2 (1-3) 
7 (5-12) 
v 
1 (1-2) 
4 (4-6) 
v 
0.5 (0-1) 
Area under the ROC curve for 
diagnosis of carcinoid heart 
disease (95% CI) 
0.988 
(0.97-1) 
0.984 
(0.96-1) 
0.995 
(0.99-1) 
0.989 
(0.97-1) 
0.964 
(0.92-1) 
0.994 
(0.99-1) 
Correlation with NTproBNP 
(P value) 
 
0.43 
(<0.0001) 
0.39 
(<0.0001) 
0.39 
(<0.0001) 
0.39 
(<0.0001) 
0.36 
(0.002) 
0.37 
(<0.0001) 
Correlation with plasma 5HIAA 
(P value) 
 
0.35 
(0.001) 
0.26 
(0.014) 
0.28 
(0.011) 
0.31 
(0.004) 
0.27 
(0.017) 
0.35 
(0.001) 
¸  Median (interquartile range), ROC – Receiver operating characteristic 
Table 5.4 Comparison of the echocardiographic scores in the patient population 
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Figure 5.1 Distribution of scores for each scoring system for patients with 
and without carcinoid heart disease 
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Scoring 
system Score 
Proportion 
at/above 
cut-point 
Sensitivity Specificity Correctly classified LR + LR - 
Bhattachary
-ya 10 16% 80 100 96% - 0.20 
 
8 21% 90 97 96% 34.7 0.10 
7 27% 95 91 92% 10.5 0.06 
6 30% 95 86 92% 6.7 0.06 
Denney 10 8% 38 100 87% - 0.62 
 
8 16% 76 100 95% - 0.24 
7 19% 86 99 96% 67.7 0.14 
6 36% 100 81 85% 5.27 0 
Dobson 8 15% 70 100 94% - 0.3 
 
7 17% 80 100 96% - 0.2 
6 20% 90 99 97% 66.6 0.1 
4 27% 100 93 95% 14.8 0 
Mansencal 7 14% 65 100 93% - 0.35 
 
6 18% 85 100 97% - 0.15 
5 23% 90 95 94% 17.1 0.11 
4 30% 100 88 90% 8.4 0 
Moller 6 17% 74 99 93% 49.4 0.27 
 
5 20% 79 97 93% 26.5 0.22 
4 27% 89 91 91% 10.3 0.12 
3 38% 95 78 81% 4.4 0.07 
Westberg 5 8% 38 100 87% - 0.62 
 
4 16% 76 100 95% - 0.24 
3 25% 100 95 96% 19.8 0 
2 34% 100 89 87% 9.3 0 
LR + Likelihood ratio positive, LR – Likelihood ratio negative 
Table 5.5 Diagnostic accuracy of the scoring systems   
  
 111 
5.4 Discussion 
 
This is the first study comparing a range of echocardiographic scoring 
systems for the quantitative assessment of carcinoid heart disease. There 
is variation in the feasibility of each of the scoring systems due to the 
varying complexity of the score components. The data demonstrate that all 
five of the established scoring systems are comparable in terms of their 
discriminatory ability for the detection of cardiac involvement. All of the 
scores correlate weakly, to a similar degree, with NTproBNP and plasma 
5HIAA. The simplest score appears to be the most optimal scoring system 
for use in screening for carcinoid heart disease whereas the more complex 
scoring systems are more suited to the patient with established disease 
who may require surgical intervention. 
 
The feasibility of the scoring systems varied according to the complexity of 
the system. Moller’s score had the lowest feasibility, due to the inclusion of 
systolic flow reversal in the hepatic veins as not all patients had adequate 
sub-costal echocardiographic images for assessment of this variable. 
Similarly those systems that included assessment of the pulmonary 
leaflets had a lower feasibility as it was not possible to adequately 
visualise the pulmonary valve in all patients. Predictably, the simplest 
scoring systems had the highest feasibility.  
 
The five established scoring systems and the new system were all able to 
accurately identify carcinoid heart disease in this cohort of patients. It 
should be noted however, that for all of the scores, it is not possible to 
create a cut-off point that is synonymous with a diagnosis of carcinoid 
heart disease. This is because patients with completely different valvular 
pathology and aetiology may have the same scores (see below). 
 
The purpose of an echocardiographic scoring system for carcinoid heart 
disease differs depending on which scoring system is used. The more 
complex scoring systems, such as the Bhattacharyya score, offer a lot 
more information than the simpler scoring systems and are therefore 
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advantageous in patients who are known to have carcinoid heart disease 
and are under consideration for valvular surgery as the surgeon would 
require as much information as possible about the valvular pathology. The 
simpler scoring systems, such as the Westberg score, are of more use in 
the screening of carcinoid heart disease, as a complex description of each 
valve is not required in these patients but discrimination between the 
presence or absence of carcinoid heart disease is paramount. 
 
Assessment of progression of carcinoid heart disease is an important 
aspect of echocardiographic screening and it is in this area that the 
scoring systems are most useful. By quantitatively assessing cardiac 
involvement using the same scoring system on an annual basis, it is 
possible to identify subtle changes in disease, and minimise error due to 
observer variation. The ideal scoring system is able to discriminate 
between those with and without carcinoid heart disease, is an accurate 
descriptor of the severity of disease and is also clinically simple to 
calculate. Ideally, it identifies those patients at highest risk of 
deterioration/progression hence requiring intervention and also reflects the 
burden of disease through its correlation with other disease markers. 
 
The morphological and functional consequences of carcinoid heart 
disease are both important aspects to include in a scoring system. The 
tricuspid valve is most frequently affected (176) therefore assessment of 
its leaflets, and the degree of tricuspid regurgitation must be included in 
any scoring system of carcinoid heart disease. The pulmonary valve is 
commonly affected (although isolated pulmonary valve carcinoid heart 
disease is rare) (54) and incorporation of this valve into a scoring system 
enhances the assessment of the burden of cardiac involvement. RV 
dilatation and dysfunction are the consequence of chronic volume 
overload and/or valvular stenosis. Inclusion of these factors in a scoring 
system provides data on the functional significance of right-sided 
involvement. 
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Involvement of left-sided cardiac structures occurs in less than ten percent 
of cases (42). There is a single case report of left sided carcinoid heart 
disease prior to right-sided disease (39). Conversely degenerative disease 
of the aortic and/or mitral valves occurs in approximately two to seven 
percent of the population aged over 65 years (177). Carcinoid heart 
disease scoring systems that include the left heart can potentially produce 
a falsely high score in a patient without carcinoid heart disease who has 
degenerative left-sided valvular disease. For example a patient with a 
calcified mitral valve and severe mitral regurgitation may score the same 
as a patient with a thickened tricuspid valve and severe tricuspid 
regurgitation, however the aetiology of the valvular diseases is likely to be 
very different. 
 
This study was a relatively small study, with only 100 patients. A large, 
prospective study is needed to assess whether the more complex 
echocardiographic scoring systems can identify minor valvular pathology 
that may have prognostic importance, and therefore enable identification 
of patients who require early surgical intervention. Furthermore, correlation 
of all the echocardiographic scoring systems with a patient symptom score 
would determine if the more complex scoring systems are able to predict a 
decline in symptoms or survival. 
 
The prevalence of carcinoid heart disease in this patient population is 
21%. This is comparable to other studies in the literature (52,54,55). The 
prevalence of significant tricuspid valve involvement in this cohort is 
similar to that described by Pellikka who reported that 90% of patients with 
carcinoid heart disease had moderate or severe tricuspid regurgitation 
(42).  
 
Screening for carcinoid heart disease using echocardiography fulfills many 
of the criteria for an effective screening programme. The disease has an 
early latent phase, echocardiography is relatively easy to perform, widely 
available, relatively cheap, and has a high sensitivity and specificity for the 
detection of the disease. The majority of patients in this study with 
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carcinoid heart disease were asymptomatic, or had exertional symptoms 
only. Regular screening of patients with metastatic NETs is clearly 
justifiable in order to facilitate early diagnosis before the development of 
RV decompensation. 
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5.5 Conclusion 
 
In conclusion, there is variation in the feasibility of the echocardiographic 
scoring systems for carcinoid heart disease, with the simplest systems 
having the highest feasibility. All of the scoring systems are comparable in 
terms of their discriminatory ability and correlation with biomarkers of 
carcinoid heart disease. However, the more complex scoring systems offer 
certain advantages over the simpler systems, as they provide a lot more 
information about both the structural and functional consequences of 
carcinoid heart disease, which is useful, particularly in the surgical setting. 
Universal standardisation of the approach to the assessment of carcinoid 
heart disease would have advantages in terms of future research studies.  
 
The simplest scoring system, devised by Westberg et al., based on 
tricuspid valve anatomy and regurgitation only, had the highest feasibility 
and was not inferior to the other scores in terms of prediction of diagnosis 
of carcinoid heart disease or correlation with NT-proBNP and plasma 
5HIAA. This simple, eight point scoring system may be the most optimal 
for use in screening of carcinoid heart disease whereas the more complex 
scoring systems are more suited to the patient with established disease 
who may require surgical intervention. 
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Abstract 
 
Introduction Carcinoid heart disease is a complication of metastatic 
NETs. The aim of this study was to identify factors associated with 
echocardiographic progression of carcinoid heart disease and death in 
patients with metastatic NETs. 
 
Methods Patients with advanced non-pancreatic NETs and documented 
liver metastases and/or carcinoid syndrome underwent prospective serial 
clinical, biochemical, echocardiographic and radiological assessment. 
Patients were categorised as carcinoid heart disease progressors, non-
progressors or deceased. Multinomial regression was used to assess the 
univariate association between variables and carcinoid heart disease 
progression.  
 
Results One hundred and thirty-seven patients were included. Thirteen 
patients (nine percent) were progressors, 95 (69%) non-progressors and 
29 (22%) patients deceased. Baseline median levels of serum NTproBNP 
and plasma 5HIAA were significantly higher in the progressors. Every 100 
nmol/L increase in 5HIAA yielded a five percent greater odds of disease 
progression (OR 1.05, 95% CI: 1.01, 1.09; P=0.012) and a seven percent 
greater odds of death (OR 1.07, 95% CI: 1.03, 1.10; P=0.001). A 100ng/L 
increase in NTproBNP did not increase the risk of progression, but did 
increase the risk of death by 11%.  
 
Conclusion The biochemical burden of disease, in particular baseline 
plasma 5HIAA concentration, is independently associated with carcinoid 
heart disease progression and death. Clinical and radiological factors are 
less useful prognostic indicators of carcinoid heart disease progression 
and/or death. 
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6.1 Introduction 
 
NETs have a heterogeneous natural history. They may follow an indolent 
course, progressing slowly over many years (9). However the 
development of carcinoid heart disease is associated with adverse clinical 
outcomes (129). Serotonin is implicated in the development of carcinoid 
heart disease (43,153), however high circulating levels of serotonin have a 
limited specificity for cardiac involvement and it is likely that there are 
other contributing factors to the pathogenesis and progression of carcinoid 
heart disease. There are limited data on factors associated with the 
progression of carcinoid heart disease in the literature. Several papers 
have identified high urinary 5HIAA levels to be independent predictors of 
progression (4,49,122).  
 
It is not known how frequently NET patients should be screened for 
carcinoid heart disease, with consensus guidelines recommending 
‘regular’ echocardiography  (126). Furthermore, there is uncertainty 
surrounding how frequently to scan those with established carcinoid heart 
disease to monitor for disease progression. Identification of factors 
associated with the development and progression of carcinoid heart 
disease may aid development of more specific, evidence-based guidelines 
both for screening, monitoring and management of the disease. 
 
No previous studies that have assessed the progression of carcinoid heart 
disease in a population of patients with liver metastases, with or without 
the carcinoid syndrome have been identified. The purpose of this 
observational cohort study was therefore to prospectively identify the 
clinical, biochemical and radiological characteristics that are associated 
with the development and progression of carcinoid heart disease and 
overall survival, in a population of patients with metastatic NETs and/or 
carcinoid syndrome. 
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6.2 Methods 
 
For an in-depth explanation of recruitment, echocardiographic, 
biochemical and statistical methods, please refer to chapter two. 
 
6.21 Assessment of Disease Severity 
 
Clinical:  Patients’ symptoms were assessed at the time of 
echocardiography, with specific questions regarding frequency of flushing, 
diarrhoea, wheezing, breathlessness and/or ankle swelling. Carcinoid 
syndrome was defined as episodes of cutaneous flushing, diarrhoea or 
wheezing.  
 
Radiological:  Baseline contrast enhanced CT imaging of the chest, 
abdomen and pelvis was performed in all patients and repeated at 12 
monthly intervals. All CT scans were reviewed by radiologists with 
expertise in the assessment of NETs and radiological progression was 
defined in accordance with the Response Evaluation Criteria in Solid 
Tumours (RECIST) guidelines (178).  
 
Echocardiographic:  Echocardiograms were performed as per the 
methods delineated in chapter two. Echocardiograms were performed at 
12 monthly intervals, or sooner if clinically indicated.  
 
6.22 Definitions of Progression 
 
Symptomatic progression was defined as >50% increase in the number of 
daily flushing episodes or bowel movements compared to the previous 
visit, as used in a similar previous study (4).  
 
Biochemical progression was defined as > 50% increase in NTproBNP or 
plasma 5HIAA from the baseline value.  
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Echocardiographic progression of carcinoid heart disease was defined as 
an increase in the degree of tricuspid regurgitation, and/or an increase in 
the degree of tricuspid leaflet thickening or immobility.  
 
6.23 Categorisation of Progression vs. Non-progression vs. Death.  
 
Patients were classified as carcinoid heart disease progressors or non-
progressors. Patients who died prior to a second echocardiogram, in 
whom assessment of progression was not possible were categorised as 
deceased. Those who died after their second scan were classified as 
either progressors or non-progressors. Where a subject died prior to the 
second echocardiographic assessment the interval between first 
assessment and date of death was recorded. The presence or absence of 
carcinoid heart disease at baseline was also noted. 
 
6.24 Inter-observer Variability 
 
Inter-observer agreement was ascertained as per the methods in chapter 
two. A randomly selected sub-group of 80 echocardiographic studies 
(58%) was cross-checked by a different observer blinded to the initial 
echocardiographic score. In 70 studies (88%) the assigned scores were 
concordant, whilst in the remaining ten studies there was discordance, 
(mean difference 0.234).  
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6.3 Results 
 
6.31 Patient Demographics 
 
One hundred and forty-eight patients were prospectively assessed for their 
eligibility to participate in the study. Four patients were lost to follow up 
and seven patients were excluded due to inadequate echocardiographic 
windows precluding clear visualisation of all valves, resulting in a total of 
137 patients studied (figure 6.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Consort flow diagram 
 
The median duration of follow up from first scan to last scan or death was 
27 months (interquartile range 12-37), with a total of 2862 patient years. 
Twenty-six patients (19%) had carcinoid heart disease at the beginning of 
the study. 
 
 
Assessed for eligibility (n=148) 
Excluded  (n=7) 
• Inadequate echocardiographic 
windows (n=7) 
 
Lost to follow-up (n=4) 
 
Total cohort  (n=137) 
Progressors (n=13) 
 
Non-progressors (n=95) 
 
Deceased (n=29) 
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6.32 Clinical Variables 
 
During the follow-up period, nine patients had echocardiographic evidence 
of progression of carcinoid heart disease and four patients developed de 
novo cardiac involvement. Twenty-nine patients died in the first year of 
follow-up, without undergoing a second echocardiogram. The baseline 
characteristics of the patient population are illustrated in table 6.1.  
 
There were no significant differences in age, gender or primary tumour site 
between the three groups. Disease duration was significantly shorter in the 
deceased group (15 months, P=0.005) but there was no difference in 
duration of disease between progressors and non-progressors (52 v 64 
months, P=0.554). Tumour grade differed significantly between the groups 
(P<0.0001) with a higher proportion of grade two (intermediate) tumours in 
the progressor group, and a higher proportion of grade three (high grade) 
tumours in the deceased group. The origin of the primary tumour in those 
with grade three disease was small bowel (one patient), stomach (one 
patient) and recto-sigmoid (two patients). All of these patients had hepatic 
metastases.  
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Variable Progression 
of CHD  
(n=13) 
No 
progression 
of CHD 
(n=95) 
Died prior 
to 2nd echo 
(n=29) 
P 
value 
Demographics 
Age (years)  
 
Male sex (no %) 
 
Follow up (months) ¸ 
68 ± 13 
 
5 (39%) 
 
29 (13-41) 
67 ± 10 
 
55 (58%) 
 
27 (12-37) 
70 ± 11 
 
16 (55%) 
 
- 
0.112 
 
0.417 
 
0.887 
Clinical Characteristics 
Tumour grade (no %) 
   Grade 1 
   Grade 2 
   Grade 3 
   Unknown 
 
Duration of disease (months) ¸  
 
Site of primary tumour: 
      Small bowel 
      Large bowel 
      Lung 
      Other 
      Unknown 
 
Liver metastases  
 
Carcinoid syndrome  
 
Baseline carcinoid heart disease  
 
Baseline echocardiographic 
score 
 
Baseline NTproBNP (ng/L) 
 
 
Baseline 5HIAA (nmol/L) 
 
1 (8%) 
3 (23%) 
0 
9 (69%) 
 
52 (27-138) 
 
 
8 (62%) 
1 (8%) 
0 
1 (8%) 
3 (24%) 
 
11 (85%) 
 
12 (92%) 
 
9 (70%) 
 
9 (7.5-14) 
 
 
267 
(108-578) 
 
2247 
(807-2939) 
 
55 (58%) 
7 (7%) 
0 
33 (35%) 
 
64 (40-88) 
 
 
71 (75%) 
7 (7%) 
1 (1%) 
1 (1%) 
15 (16%) 
 
80 (84%) 
 
63 (66%) 
 
5 (5%) 
 
3 (1-5) 
 
 
84 
(29-224) 
 
316 
(138-661) 
 
9 (31%) 
2 (7%) 
4 (14%) 
14 (48%) 
 
15 (9-59) 
 
 
19 (66%) 
1 (3%) 
2 (7%) 
3 (10%) 
4 (14%) 
 
27 (93%) 
 
21 (72%) 
 
12 (41%) 
 
5 (2.5-14.5) 
 
 
401 
(116-978) 
 
1221 
(167-4370) 
 
0.007 
 
 
 
 
0.005 
 
 
0.126 
 
 
 
 
 
0.473 
 
0.151 
 
<0.001 
 
<0.001 
 
 
0.001 
 
 
0.009 
 
Therapeutic Intervention 
SSA therapy  
 
Primary tumour resection 
 
Resection of hepatic metastases 
 
Interferon 
 
Chemotherapy 
 
Targeted radio-nuclide therapy  
 
Chemo-embolisation 
 
Radio-frequency ablation 
12 (92%) 
 
6 (46%) 
 
1 (8%) 
 
0 
 
0 
 
4 (31%) 
 
1 (8%) 
 
0 
78 (82%) 
 
63 (66%) 
 
9 (10%) 
 
8 (8%) 
 
10 (10%) 
 
27 (28%) 
 
11 (12%) 
 
6 (6%) 
17 (59%) 
 
7 (24%) 
 
2 (7%) 
 
2 (7%) 
 
6 (21%) 
 
4 (14%) 
 
0 
 
0 
0.012 
 
<0.001 
 
0.903 
 
0.547 
 
0.111 
 
0.259 
 
0.154 
 
0.25 
  Mean ± standard deviation, ¸ Median and interquartile range 
 
Table 6.1 Baseline characteristics of patients 
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Worsening of carcinoid syndrome symptoms was associated with 
progression of carcinoid heart disease. Eighty-five percent of those with 
symptom deterioration demonstrated progression of carcinoid heart 
disease compared with five percent of those with no symptom 
deterioration (P<0.001, table 6.3). Although worsening of symptoms was 
independently associated with progression of carcinoid heart disease; OR 
99 (95% CI 17-573, P<0.001, table 6.2) the wide confidence interval 
implies some uncertainty in this estimate. 
 
The numbers of patients that underwent primary tumour resection or 
received SSAs were significantly different between the groups (table 6.1). 
There was however, no difference in the proportions of patients 
undergoing hepatic resection, trans-arterial chemo-embolisation, targeted 
radionuclide therapy, radiofrequency ablation or chemotherapy between 
the groups. The risk of death in those who had not had a primary tumour 
resection was approximately 3.7 times greater than in those who had 
undergone a primary resection (OR 3.72, 95% CI: 1.60-8.69; P<0.002) but 
primary resection did not increase the odds of carcinoid heart disease 
progression (OR 2.30, 95% CI: 0.71-7.40; P=0.164). 
 
6.33 Biochemical Variables 
 
Baseline plasma 5HIAA and NTproBNP concentrations were significantly 
different between the groups (table 6.1 & figure 6.2) with the highest 
NTproBNP levels seen in the deceased group and the highest 5HIAA 
concentrations in the progressors. Baseline 5HIAA concentration was 
significantly associated with disease progression: every 100 nmol/L 
increase in 5HIAA yielded a five percent greater odds of disease 
progression (OR 1.05, 95% CI: 1.01, 1.09; P=0.012) and a seven percent 
higher odds of death before second follow-up (OR 1.07, 95% CI: 1.03, 
1.10; P=0.001, see table 6.2). The proportion of patients with NTproBNP 
or 5HIAA progression was significantly higher in the progressors 
 125 
compared to the non-progressors (62% v 31%, P=0.04 and 46% v 18%, 
P=0.035 respectively, see table 6.3). 
 
 
      
 
   
Figure 6.2 Baseline 5HIAA and NTproBNP according to patient group 
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6.34 Radiological Variables 
 
Increase in tumour bulk was not associated with progression of carcinoid 
heart disease. Ten percent of those with stable disease demonstrated 
progression of carcinoid heart disease compared to 13% of those with an 
increase in tumour bulk (P=0.669), OR 0.76 (95% CI 0.22-2.66, P=0.670, 
table 6.2).  
 
Variable Unit change Group OR (95% CI) P value 
Age (years) 5 years 
 
5 years 
Progression 
 
Death 
1.09 (0.82-1.45) 
 
1.16 (0.94-1.43) 
0.570 
 
0.167 
Disease duration 
(months) 
100 months 
 
100 months 
Progression 
 
Death 
0.99 (0.36-2.72) 
 
0.22 (0.07-0.73) 
0.986 
 
0.013 
Symptom deterioration - Progression 99 (17-573) <0.001 
Baseline NTproBNP 
(ng/L) 
100 units 
 
100 units 
Progression 
 
Death 
1.04 (0.92-1.18) 
 
1.11 (1.02-1.21) 
0.486 
 
0.014 
Baseline 5HIAA 
(nmol/L) 
100 units 
 
100 units 
Progression 
 
Death 
1.05 (1.01-1.09) 
 
1.07 (1.03-1.10) 
0.012 
 
0.001 
Radiological increase 
in tumour bulk 
- Progression 0.76 (0.22-2.66) 0.670 
 
Table 6.2 Multinomial logistic regression analysis 
 
 
Variable Progression of 
carcinoid heart 
disease 
(n=13) 
No progression 
of carcinoid 
heart disease 
(n=95) 
P value 
Symptomatic deterioration Δ 11 (85%) 5 (5%) <0.001 
NTproBNP progression Ψ 8 (62%) 24 (31%) 0.04 
Plasma 5HIAA progression Ψ 6 (46%) 14 (18%) 0.035 
Radiological progression ϒ 4 (31%) 35 (37%) 0.461 
Δ > 50% increase in the number of daily flushing episodes or bowel movements 
compared to the previous visit 
Ψ  > 50% increase from the baseline value 
ϒ in accordance with RECIST (Response Evaluation Criteria in Solid Tumors) guidelines 
 
Table 6.3 Association of variables with progression of carcinoid heart 
disease 
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6.35 Carcinoid Heart Disease Score 
 
Increasing echocardiographic score was an independent predictor of both 
carcinoid heart disease progression and death. A five-point increase in the 
score was associated with an OR of 2.95 (95% CI 1.71-5.09, P<0.005) for 
carcinoid heart disease progression and 2.66 (95%CI 1.63-4.35, P<0.005) 
for death.  
 
6.36 Death 
 
The deceased patients had significantly shorter durations of disease (15 
months v 64 months in the non-progressors and 52 months in the 
progressors, P=0.005). They also had histologically more aggressive 
tumours (14% high grade v 0% in the other groups, P<0.001). Of the 29 
deceased patients, 12 (41%) had carcinoid heart disease. In a univariate 
Cox proportional hazard model, the risk of death in those with carcinoid 
heart disease at baseline was significantly greater than in those without 
carcinoid heart disease (hazard ratio 3.61, 95% CI (1.69 - 7.69), P=0.001). 
Figure 6.3 shows Kaplan Meier survival estimates according to presence 
or absence of baseline carcinoid heart disease. 
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Figure 6.3 Effect of baseline carcinoid heart disease on survival  
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6.4 Discussion 
 
This large, prospective, observational cohort study has demonstrated that 
biochemical variables, in particular baseline plasma 5HIAA concentration, 
are independently associated with carcinoid heart disease progression in 
patients with metastatic NETs and have greater prognostic value than 
clinical or radiological variables. 
 
The finding of the value of plasma 5HIAA concentration in the prediction of 
carcinoid heart disease progression is consistent with results from 
Bhattacharyya et al. and Moller et al. who demonstrated similar 
associations between carcinoid heart disease progression and urinary 
5HIAA concentrations (4,122). Serotonin is a major biochemical mediator 
of carcinoid heart disease (179,180) and therefore the measurement of its 
main metabolite, 5HIAA, is a logical biomarker to measure. Plasma 
measurement of 5HIAA is easier for the patient, and correlates well with 
the more traditional 24-hour urinary measurement (67). The data 
demonstrate that both NTproBNP and 5HIAA are independently 
associated with death in patients with metastatic NETS and/or carcinoid 
syndrome. An elevated NTproBNP concentration may reflect other factors 
known to increase risk of death such as NYHA class III-IV or RV dilatation. 
Biochemical measurement is, however, a more objective measurement 
than attempting to evaluate NYHA class which is notoriously difficult to 
estimate (181). 
 
Patients with symptomatic deterioration were more likely to demonstrate 
carcinoid heart disease progression than those with stable symptoms. This 
finding is similar to that of Bhattacharyya et al. and is likely to be due to 
higher serotonin levels in the patients with worsening symptoms of the 
carcinoid syndrome. Use of SSA therapy was more common in the 
progressors, which may be a reflection of more advanced disease in this 
patient group.  
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This study found no relationship between radiological progression and 
progression of carcinoid heart disease. However, resection of the primary 
tumour was more common in the non-progressors than in the progressors 
or deceased groups. This may support previous findings suggesting that a 
reduction in tumour burden by hepatic resection may decrease the risk of 
progression of carcinoid heart disease through the reduction in circulating 
hormone levels  (124).  
 
The rate of progression of carcinoid heart disease is difficult to estimate 
due to the number of deaths in this study (no progression data available 
for these patients). The progression rate could be as low as ten percent 
(13/137) or as high as 31% (42/137), but is likely to fall somewhere within 
this range, in keeping with the progression rates of similar studies (4,122).  
 
There are several limitations to this study. First is the lack of a 
standardised definition of carcinoid heart disease progression, although 
this limitation can be applied to all similar studies. As the 
echocardiographic score assesses both sides of the heart, an increase in 
the score could be due to co-existing pathology such as degenerative 
mitral valve disease, and therefore using an absolute increase in the 
echocardiographic score as the determinant of carcinoid heart disease 
progression would lead to an overestimate of the number of patients 
demonstrating progression. For this reason a clinical definition was used. 
The author also acknowledges the relatively short duration of follow up in 
the study and the heterogeneity of the study population with differences in 
tumour biology/grade, types and duration of treatment modalities and 
duration of diagnosis. This limitation may be overcome in larger, perhaps 
national studies, in which common therapeutic pathways and algorithms 
may be adopted and longer-term outcome available. Finally cause of 
death was unknown and it is uncertain in all individuals whether death was 
attributable to NET disease progression, to carcinoid heart disease 
progression or to an unrelated cause.  
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6.5 Conclusion 
 
The findings of this study suggest that it is the biochemical or hormonal 
burden of disease, rather than radiological extent or duration of disease 
that dictates development and progression of carcinoid heart disease. This 
implies that any treatments, medical (e.g. SSAs) or surgical (resection of 
primary tumour) that reduce secretion of vasoactive substances may be 
protective against the development and progression of carcinoid heart 
disease.  
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Chapter 7: Discussion 
 
 
7.1 Introduction  
 
7.2 Variation in screening for and management of carcinoid heart 
disease  
 
7.3 Biochemical markers of presence and severity of carcinoid heart 
disease 
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7.6 Conclusion and future directions 
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7.1 Introduction 
 
Carcinoid heart disease, a rare form of valvular heart disease, is an 
important complication of neuroendocrine disease. Due to a lack of data 
within the literature, there is considerable heterogeneity within 
international consensus guidelines for this condition. This project was 
conducted to add to the evidence base for carcinoid heart disease so that 
some of the gaps in the literature could be addressed and clearer 
guidelines for the condition could be developed. 
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7.2 Variation in Screening for and Management of 
Carcinoid Heart Disease 
 
Screening for carcinoid heart disease amongst patients with metastatic 
NETs is imperative in order to identify patients who may have 
asymptomatic cardiac involvement, before they develop irreversible RV 
dysfunction. Due to inconsistencies in international guidelines, it was 
suspected that clinical practice varied considerably with respect to 
carcinoid heart disease across the UK and Republic of Ireland.  
 
In chapter three it was demonstrated that compliance with current UK 
guidelines for carcinoid heart disease is relatively poor. It was found that 
the management of carcinoid heart disease is often sub-standard, 
reflected by the wide variations in the population screened, in the 
frequency and mode of screening and in access to local cardiology 
expertise.  
 
Standardisation of nationwide practice in the management of carcinoid 
heart disease in accordance with a consensus guideline would facilitate a 
UK registry of patients with carcinoid heart disease to better understand 
the natural history and prognosis of this condition and potentially improve 
patient outcomes for the disease across the UK and Ireland.  
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7.3 Biochemical Markers of Presence and Severity of 
Carcinoid Heart Disease 
 
Biochemical markers are useful clinical aids in the assessment of 
carcinoid heart disease. A variety of biomarkers have been investigated 
for the diagnostic and prognostic assessment of carcinoid heart disease 
but many have limited clinical utility due to difficulties in their 
measurement, false-positive results or lack of data (29,55,68,71,175).  
 
In chapter four a panel of biomarkers (NTproBNP, 5HIAA, CgA, CgB and 
NkA) was investigated and it was demonstrated that the median 
concentrations of all five biomarkers are significantly higher in patients 
with carcinoid heart disease compared to those with metastatic NETs and 
no evidence of carcinoid heart disease. However NTproBNP and plasma 
5HIAA have the greatest discriminatory value in the diagnosis of carcinoid 
heart disease. 
 
We advocate the use of NTproBNP in patients with metastatic NETs as a 
tool to assess the presence of cardiac involvement. We propose that all 
such patients undergo a baseline echocardiogram at diagnosis or initial 
assessment, and if there is no evidence of cardiac involvement, 
echocardiography is only repeated in the event of an increase in 
NTproBNP.  
 
It is likely that, with continued research, new biomarkers with increased 
specificity and sensitivity for carcinoid heart disease will be identified and 
used in the future. 
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7.4 Echocardiographic Assessment of Carcinoid Heart 
Disease 
 
Transthoracic echocardiography is the key imaging modality for the 
evaluation of carcinoid heart disease.  The chronic and progressive nature 
of the disease mandates serial assessment in order to identify progression 
of cardiac involvement, an important aspect of managing patients with 
NETs.   
 
A range of echocardiographic scoring systems have been described in the 
literature for the quantitative assessment of carcinoid heart disease 
(49,50,53,122,123). Chapter five compares these scoring systems and 
investigates their differing uses.   
 
Variation in the feasibility of each of the scoring systems was identified, 
however all of the established echocardiographic scoring systems, and a 
newly devised scoring system, were able to accurately discriminate 
between NET patients with and without carcinoid heart disease. 
 
The simplest scoring system, devised by Westberg et al., (50) was the 
most optimal for use in the screening of carcinoid heart disease. The more 
complex and comprehensive scoring systems were more suited to the 
patient with established disease, who requires serial echocardiograms and 
who may require surgical intervention.  
 
Universal standardisation of the echocardiographic approach to the 
assessment of carcinoid heart disease would have advantages in terms of 
future research studies and would enable a structured, cohesive approach 
to all patients with metastatic NETs. 
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7.5 Progression of and Mortality From Carcinoid Heart 
Disease 
 
Progression of carcinoid heart disease is an adverse prognostic sign (50). 
There are limited data on factors associated with the progression of 
carcinoid heart disease in the literature, due, in part, to the lack of a 
standardised definition of progression of carcinoid heart disease. Several 
papers have identified a high urinary 5HIAA level to be independent 
predictor of progression (4,49,122).  
 
In chapter six the effect of biochemical, radiological and clinical variables 
on the progression of carcinoid heart disease was investigated. The data 
demonstrate that biochemical variables, in particular baseline plasma 
5HIAA concentration, are independently associated with carcinoid heart 
disease progression in patients with metastatic NETs and have greater 
prognostic value than clinical or radiological variables.  
 
With regard to mortality, the data demonstrate that both NTproBNP and 
5HIAA are independently associated with death in patients with metastatic 
NETS and/or carcinoid syndrome. This implies that any treatments, 
medical (e.g. SSAs) or surgical (resection of primary tumour) that reduce 
secretion of vasoactive substances may be protective against the 
development and progression of carcinoid heart disease.  
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7.5 Conclusion and Future Directions 
 
This thesis has attempted to address the gaps in the literature with regard 
to the screening, diagnosis and progression of carcinoid heart disease.   
 
• There is wide variation in clinical practice with respect to screening 
methods for carcinoid heart disease and there is a need for a 
comprehensive, consensus guideline on the screening and 
management of carcinoid heart disease in order to standardise the 
clinical approach and optimise patient care. 
• NTproBNP and plasma 5HIAA have the greatest discriminatory 
value in the diagnosis of carcinoid heart disease and should be 
used in the screening and assessment of the disease. 
• The Westberg scoring system is the most optimal for use in the 
screening of carcinoid heart disease whereas the more complex 
scoring systems are more suited to the patient with established 
disease who may require surgical intervention.  
• Biochemical variables, in particular baseline plasma 5HIAA 
concentration, are independently associated with carcinoid heart 
disease progression in patients with metastatic NETs and have 
greater prognostic value than clinical or radiological variables. 
 
There are still some questions left to be answered, which require further 
research.  In particular, we have not yet ascertained why only 20% of 
patients with carcinoid syndrome develop carcinoid heart disease, or what 
protects the other 80% of patients. Despite a theoretical advantage of 
treating carcinoid heart disease with SSAs, we have been unable to 
demonstrate any clear benefit in terms of a lower incidence of the disease 
or delayed progression of the condition. This may be explained by a 
treatment bias (the most symptomatic patients are the most likely to have 
the highest 5HIAA levels and be using SSAs). Further research is required 
to address these issues and better integration between NET centres and 
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greater centralisation of care is also required to optimise management of 
this important condition. 
 
At a local level, the author has produced a screening protocol for carcinoid 
heart disease for the NET centres involved in the project and has 
established a dedicated cardiologist on the NET multi-disciplinary team at 
the base site. 
 
Since the completion of this project, the UK guidelines for the screening 
and management of carcinoid heart disease have been re-developed with 
a more up-to-date evidence base (in progress).  The work contained within 
this thesis has contributed to the drafting of these guidelines and the 
author of this thesis is one of the guideline’s 12 co-authors.   
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Consent form (V 3, 2012) 
Centre Number: 
Patient Identification Number for this trial: 
Title of Project: Improving our understanding of carcinoid heart disease 
Name of Researcher: Dr. Rebecca Dobson                                   
Please initial 
boxes                                                                                                                                         
  to confirm  
•  I confirm that I have read and understand the information sheet 
dated ......................... (version ............) for the above study.    
•  I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily.     
•  I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected.  
   
•  
I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to 
my records.  
   
•  I agree to my GP being informed of my participation in the study.    
•  I agree to take part in the above research study.     
 
__________________________ 
Name of Patient  
______________ 
Date 
 
__________________________ 
Signature 
 
__________________________ 
Name of Person taking consent  
(if different from researcher) 
______________ 
Date 
__________________________ 
Signature 
 
__________________________ 
Researcher 
 
______________ 
Date 
 
__________________________ 
Signature 
When complete, 1 copy for patient: 1 copy for researcher site file: 1 (original) to be kept in 
medical notes. 
 
Appendix I Consent Form 
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Improving our understanding of carcinoid heart disease 
(Using novel biochemical and genetic markers to predict severity of carcinoid 
heart disease described using modern echocardiographic techniques.) 
Participant Information Sheet 
 
Invitation 
We invite you to participate in a research project. Before you decide we need to 
ensure you understand why the project has been set up and what it involves. 
 
Please read through this leaflet carefully. You may, if you wish, discuss this with 
family, friends or your GP. We will be available to explain and provide any 
further information you may require. You do not have to make an immediate 
decision. 
 
As your GP is your primary care provider we will inform your GP of your 
participation in this study. Your GP will receive an information sheet similar to 
this. 
 
Background 
Carcinoid tumours are a form of slow growing cancer, which is often associated 
with a very good outlook. Carcinoid tumours may arise from anywhere but are 
predominantly found in the digestive tract (bowel). At diagnosis it is common to 
find the Carcinoid tumour has spread from the digestive tract to the peritoneum 
(the outer lining of the bowel) and/or the liver a process called metastasis. The 
outlook for patients with carcinoid tumours and metastases is good, unlike many 
other cancers. 
 
Patients with carcinoid tumours may have no symptoms. Some patients 
(approximately 1 in 4) experience flushing (intense redness commonly of the 
face) and diarrhoea. This combination of symptoms is referred to as Carcinoid 
syndrome. Hormones produced by the tumour cause carcinoid syndrome. Not all 
Carcinoid tumours produce hormone and in many cases the hormone produced is 
removed in the liver before it can produce symptoms. Carcinoid syndrome is more 
common in patients who have liver metastasis. 
 
The same hormones that produce the symptoms of the Carcinoid syndrome may 
also cause damage to the valves on the right side of the heart (tricuspid and 
pulmonary valves), called Carcinoid Heart Disease (CHD). There is currently no 
evidence on who is most likely to develop CHD, when it develops, or how to 
screen for it. CHD does not usually require active management. However, rarely, 
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surgery is required to replace the damaged valve. In these situations valve surgery 
has been shown to improve outcome.  
 
It is usual practice for patients with carcinoid tumours to have assessments every 
6-12 months. These will include blood and urine tests and an echocardiogram 
(heart scan). As we are interested in carcinoid disease we would like to take some 
additional blood and urine tests and additional echocardiographic images. 
 
 Reproduced with permission NET patient foundation 
 
What does the study involve? 
 
You will be asked to see Dr. Rebecca Dobson (study investigator) in a private 
examination room. She will ask you to give written consent to take part in the 
study. With your permission the following tests will be performed: 
Blood samples 
A needle will be inserted into a vein in your arm.  We will use this to take 
approximately 20mls (4 teaspoons full) of blood. The needle will then be 
removed. 
Echocardiogram 
An echocardiogram is an ultrasound scan of the heart. Ultrasound is a technology 
which uses high frequency sound waves (above the audible range) to form an 
image. This is the same technology that is used to look at unborn children and is 
completely safe. During the scan a probe is placed in particular regions on your 
chest the image being acquired through the probe. The image is improved with the 
use of a water-based gel (applied to the skin on the chest) which wipes off at the 
end of the procedure. This whole process will take between 30-45minutes. 
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Possible disadvantages and risks of taking part 
The risks involved in blood sampling are very small. Occasionally there is mild 
bruising due to leakage from a blood vessel but this is rare with good practice. 
 
There are no risks in collecting additional echocardiographic images.  
 
Occasionally we may find an unexpected abnormality (unrelated to the study), 
which may require medical follow-up with either further investigation or (more 
rarely) treatment. If this is the case we will send a report to your GP and your 
consultant allowing prompt investigation and treatment. 
 
The tests we will perform are an extension of normal clinical care so we will not 
be offering financial reimbursement. 
 
What happens to the blood samples that have been taken? 
The samples taken will be stored securely in University Hospital Aintree. They 
will then be analysed  and the results anonymised (i.e. linked to a special code that 
is stored separately on a password protected computer file) and stored on a 
computer file. The computer file will be stored on a secure University computer in 
the Clinical Sciences Building University Hospital Aintree. Only members of the 
research team will have access to your details, samples and results.  Samples will 
be sent for analysis to the Royal Victoria Hospital, Belfast, and to the University 
Hospital of South Manchester (Wythenshawe Hospital). 
 
How long will it take? 
The additional tests will take 60 minutes. You will be asked to return for a further 
similar assessment in 6-12 months. 
 
Audit 
In studies such as this it is a requirement for the data collected to be available for 
review by an external professional body for the purpose of audit (to check the data 
is collected in the proper manner). Should this be required the data will be made 
available. 
 
Finally I would like to reassure you that if you do not participate your treatment 
will not be compromised. If you decide to participate you are free to withdraw at 
any time. If you desire any data collected, as part of the project, relating to you 
can be erased. 
 
Contact numbers: 
If there are any questions please contact:  
Dr Rebecca Dobson 
Specialist Registrar in Cardiology 
Clinical Sciences Centre, 
University Hospital Aintree, 
University of Liverpool. 
L9 7AL 
Email: rebecca.dobson@liverpool.ac.uk 
Tel: 0151 5295917 
 144 
 
Original Article
Variation in Cardiac Screening and Management of Carcinoid Heart
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Abstract
Aims: Screening for carcinoid heart disease is an important, yet frequently neglected aspect of the management of patients with neuroendocrine tumours
(NETs). Screening is advocated in international guidelines, although recommendations on the modality and frequency are poorly deﬁned. We mapped current
practice for the screening and management of carcinoid heart disease in specialist NET centres throughout the UK and Republic of Ireland.
Materials and methods: Thirty-ﬁve NET centres were invited to complete an online questionnaire outlining the size of NET service, patient selection criteria for
carcinoid heart disease screening and the modality and frequency of screening.
Results: Twenty-eight centres responded (80%), representing over 5500 patients. Eleven per cent of centres screen all patients with any NET, 14% screen only
patients with midgut NETs, 32% screen all patients with liver metastases and/or carcinoid syndrome and 43% screen all patients with evidence of syndrome or
raised urinary/serum/plasma 5-hydroxyindoleacetic acid (5HIAA). The mode of screening included clinical examination, echocardiography and biomarker
measurement: 89% of centres carry out echocardiography, ranging from at initial presentation only (24%), periodically without clearly deﬁned intervals (28%),
annually (36%) or less than annually (12%); three centres use a scoring system to report their echocardiograms. Fifty per cent of centres utilise biomarkers for
screening (chromogranins, plasma/urinary 5HIAA or most commonly N-terminal pro-brain natriuretic peptide) at varying time intervals.
Conclusion: There is considerable heterogeneity across the UK and Ireland in multiple aspects of screening and management of carcinoid heart disease.
! 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Key words: Carcinoid heart disease; management; neuroendocrine; screening
Introduction
Carcinoid heart disease is a complication of metastatic
neuroendocrine disease and occurs in 20e50% of patients
with the carcinoid syndrome [1,2]. The cardiac manifesta-
tions of neuroendocrine tumours (NETs) are a consequence
of tumour secretion of vasoactive substances such as sero-
tonin, prostaglandins, tachykinins and histamine [3,4]. He-
patic metastases enable these substances to reach the right
heart without being inactivated [5]. Rarely, carcinoid heart
disease may occur in the absence of liver metastases, for
example, in primary ovarian NETs, when the ovarian venous
drainage bypasses the portal venous system [6,7].
Carcinoid heart disease can be clinically silent, with no
symptoms or signs of disease, even in patients with
advanced pathology [8,9]. However, cardiac involvement
has signiﬁcant prognostic implications; a 3 year survival for
patients with carcinoid heart disease of 31% compared with
68% for those with no cardiac involvement [10]. The prog-
nosis has improved in recent years, with the median sur-
vival about 4 years from diagnosis [11], but this is still
signiﬁcantly shorter than themedian survival duration of 10
years of patients with grade 1 NETs [12]. As moderate to
severe right ventricular dilatation and New York Heart As-
sociation Class IIIeIV symptoms are associated with
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University Hospital, Longmoor Lane, Liverpool L9 7AL, UK. Tel: þ44-151-
529-5917; Fax: þ44-151-529-5888.
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The Association of a Panel of Biomarkers with the
Presence and Severity of Carcinoid Heart Disease: A
Cross-Sectional Study
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Abstract
Purpose: Metastatic neuroendocrine tumors secrete serotonin and other vasoactive substances that are responsible for
carcinoid syndrome and carcinoid heart disease. We sought to evaluate the discriminatory utility of diagnostic biomarkers in
determining the presence and severity of carcinoid heart disease in patients with metastatic neuroendocrine tumors.
Patients and methods: A cross-sectional study of patients with neuroendocrine tumors with documented liver metastases
and/or carcinoid syndrome between April 2009–October 2012 in 5 tertiary referral centers. Serum was analyzed for
Chromogranin A, Chromogranin B and N-terminal pro Brain Natriuretic Peptide (NT-proBNP). Plasma was analyzed for
Neurokinin A and 5-Hydroxyindoleacetic acid (5HIAA). Echocardiography was used to determine the presence and severity
of carcinoid heart disease. Non-parametric receiver operating characteristic curves were constructed for biomarkers, and the
area under the curve determined. The severity of cardiac involvement was correlated with the concentration of each
biomarker.
Results: A total of 187 patients were identified of whom 37 (20%) had carcinoid heart disease. Significantly higher median
values of all biomarkers were found in the patients with cardiac involvement. NT-proBNP and plasma 5HIAA had the highest
areas under the curve for the prediction of carcinoid heart disease [NT-proBNP 0.82 (95% confidence interval 0.74–0.90,
p,0.0001) and 5HIAA 0.85 (95% confidence interval 0.78–0.92, p,0.0001]. NT-proBNP was moderately correlated (r = 0.48,
p,0.001) whereas plasma 5HIAA was only weakly correlated (r = 0.34, p,0.001) with the echocardiographic severity score.
Conclusion: NT-proBNP and plasma 5HIAA are both sensitive and specific biomarkers for the presence of carcinoid heart
disease whereas only NT-proBNP is moderately correlated with disease severity.
Citation: Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, et al. (2013) The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid
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Introduction
Metastatic mid-gut neuroendocrine tumors (NETs) secrete
serotonin and a variety of other vasoactive substances that are
responsible not only for the characteristic carcinoid syndrome, but
also for the significant long-term complication of carcinoid heart
disease.
The pathophysiology of carcinoid heart disease has been
elucidated from human and animal studies with increased plasma
concentrations of serotonin strongly implicated from several lines
of evidence. The specific serotonin re-uptake inhibitors fenflur-
amine and dexfenfluramine, used as appetite-suppressant drugs,
and the ergot alkaloids, ergotamine and methysergide, used in the
treatment of migraine, are known to cause valvular fibrosis [1,2].
Secondly, in an in vivo rodent model of carcinoid syndrome, in
which there are significant increases in plasma serotonin, mice
exhibited fibrotic cardiac valvular disease, which was abrogated by
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73679
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CHD. All scores discriminated highly between those with/
without CHD, with no single score performing significantly 
better than another. The severity, determined using all of the 
scoring systems, correlated with the concentration of both 
biomarkers, but the strongest correlations were seen be-
tween the Bhattacharyya score and serum NT-proBNP.  Con-
clusion: All scoring systems are comparable in terms of sen-
sitivity and specificity for the detection of CHD. There is a 
variation in the feasibility of the scoring systems due to vary-
ing complexity of the score components. All scores correlate 
with NT-proBNP and plasma 5-HIAA. The Westberg score ap-
pears to be the most optimal scoring system for use in 
screening of CHD whereas the more complex scoring sys-
tems are more suited to the patient with established disease 
who may require surgical intervention. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Carcinoid heart disease (CHD) occurs in up to 50%
of patients with carcinoid syndrome  [1] . It is mediated
by serotonin released from neuroendocrine tumours 
(NETs), which is metabolised to 5-hydroxyindoleacetic 
 Key Words 
 Carcinoid heart disease · Echocardiography · Scoring 
system 
 Abstract 
 Background: Carcinoid heart disease (CHD) is an important 
complication of metastatic neuroendocrine disease, requir-
ing regular monitoring to enable intervention prior to right 
heart failure. We aimed to identify the most appropriate 
echocardiographic scoring systems for the quantitative as-
sessment of CHD.  Methods: In this prospective study con-
ducted between April and October 2012 in two European 
Neuroendocrine Tumor Society (ENETS) Centres of Excel-
lence, patients with neuroendocrine tumours with liver me-
tastases and/or carcinoid syndrome underwent transthorac-
ic echocardiography and blood sampling for serum N-termi-
nal pro-brain natriuretic peptide (NT-proBNP) and plasma 
5-hydroxyindoleacetic acid (5-HIAA). Each patient was as-
sessed according to six echocardiographic scoring systems. 
The individual scoring systems’ feasibility, observer variabil-
ity, sensitivity, specificity and correlation with the concentra-
tion biomarkers were determined.  Results: 100 patients 
were included; 21% had echocardiographic evidence of 
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Serial surveillance of carcinoid heart disease:
factors associated with echocardiographic
progression and mortality
R Dobson*,1,2, M I Burgess1,3, J W Valle4, D M Pritchard5,6, J Vora6, C Wong1, C Chadwick1, B Keevi7,
J Adaway7, U Hofmann8, G J Poston1 and D J Cuthbertson1,2
1Neuroendocrine Tumour Group, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK; 2Department of Obesity &
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University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK; 4Manchester Academic Health Sciences Centre, Department of
Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK; 5Department of
Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, UK; 6Neuroendocrine Tumour
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Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK and 8Medical Oncology, Huddersfield
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Background: Carcinoid heart disease is a complication of metastatic neuroendocrine tumours (NETs). We sought to identify
factors associated with echocardiographic progression of carcinoid heart disease and death in patients with metastatic NETs.
Methods: Patients with advanced non-pancreatic NETs and documented liver metastases and/or carcinoid syndrome underwent
prospective serial clinical, biochemical, echocardiographic and radiological assessment. Patients were categorised as carcinoid
heart disease progressors, non-progressors or deceased. Multinomial regression was used to assess the univariate association
between variables and carcinoid heart disease progression.
Results: One hundred and thirty-seven patients were included. Thirteen patients (9%) were progressors, 95 (69%) non-progressors
and 29 (21%) patients deceased. Baseline median levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and
plasma 5-hydroxyindoleacetic acid (5-HIAA) were significantly higher in the progressors. Every 100 nmol l! 1 increase in 5-HIAA
yielded a 5% greater odds of disease progression (OR 1.05, 95% CI: 1.01, 1.09; P¼ 0.012) and a 7% greater odds of death (OR 1.07,
95% CI: 1.03, 1.10; P¼ 0.001). A 100 ng l! 1 increase in NT-proBNP did not increase the risk of progression, but did increase the risk
of death by 11%.
Conclusions: The biochemical burden of disease, in particular baseline plasma 5-HIAA concentration, is independently associated
with carcinoid heart disease progression and death. Clinical and radiological factors are less useful prognostic indicators of
carcinoid heart disease progression and/or death.
Neuroendocrine tumours (NETs) have a heterogeneous natural
history. They often follow an indolent course, progressing slowly
over many years (Bhattacharyya et al, 2007). However, the
development of carcinoid heart disease is associated with adverse
clinical outcomes (Fox and Khattar, 2004). Cardiac involvement is
characterised by right-sided valvular dysfunction, which can
progress to right ventricular dilatation and failure. Serotonin is
implicated in the development of carcinoid heart disease (Robiolio
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